var title_f35_40_36480="Sleeve gastrectomy";
var content_f35_40_36480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=86\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=86\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Sleeve gastrectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a sleeve gastrectomy the majority of the greater curvature of the stomach is removed and a tubular stomach is created. The tubular stomach has a small capacity, is resistant to stretching due to the absence of the fundus, and has few ghrelin producing cells (a gut hormone involved in regulating food intake).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36480=[""].join("\n");
var outline_f35_40_36480=null;
var title_f35_40_36481="Breast cancer screening";
var content_f35_40_36481=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Breast cancer screening (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/40/36481/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36481/contributors\" id=\"au4183\">",
"       Suzanne W Fletcher, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/40/36481/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36481/contributors\" id=\"se2926\">",
"       Julie R Gralow, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/40/36481/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36481/contributors\" id=\"de162\">",
"       H Nancy Sokol, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/40/36481?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Breast cancer screening includes tests to detect breast cancer at an early stage, before a woman discovers a lump. The chance of dying from breast cancer has declined by about a third over the past few decades. This is due, in part, to the use of breast cancer screening to find cancer at an earlier stage. Breast cancer is more likely to be cured when it is caught earlier.",
"    </p>",
"    <p>",
"     This article discusses what breast cancer screening includes, when it should start, and how often it should be done. Women with a high risk of breast cancer, such as those with a genetic mutation in BRCA1 and BRCA2 and those who have multiple close relatives with breast cancer should review information about genetic testing and screening recommendations in higher risk individuals. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/15/30963?source=see_link\">",
"      \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BREAST CANCER SCREENING METHODS",
"     </span>",
"    </p>",
"    <p>",
"     There are three main ways to screen for breast cancer: mammogram, breast exam with your doctor or nurse, and breast self-exam.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Mammogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;A mammogram is a breast x-ray. It is the best screening test for reducing the risk of dying from breast cancer. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"      \"Breast imaging: Mammography and ultrasonography\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Before the mammogram, you will be asked to undress from the waist up and wear a hospital gown. Each breast is x-rayed individually. The breast is flattened between two panels. This can be uncomfortable, but it only takes a few seconds. If possible, try to avoid scheduling your mammogram just before or during your menstrual period, when the breasts are more sensitive. Also, do not use underarm deodorant on the day of your appointment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Mammogram results",
"     </span>",
"     &nbsp;&mdash;&nbsp;A radiologist will review and interpret the mammogram. Sometimes the radiologist reviews the mammogram images while you wait. Some women will need to have more images taken. Needing more images is common and does not usually mean that you have cancer. These extra images help the radiologist to have the most accurate and clear view of your breast tissue.",
"    </p>",
"    <p>",
"     If the radiologist does not review your mammogram immediately, you should get a phone call or letter with your results within 30 days. If you do not hear back about your results, call your doctor or nurse's office. You should not assume that your mammogram was normal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      What if my mammogram is abnormal?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your mammogram is abnormal, you will need further testing. In most cases, a woman with an abnormal mammogram does not have breast cancer. In 90 percent of women with an abnormal mammogram, breast cancer is",
"     <strong>",
"      not",
"     </strong>",
"     found.",
"    </p>",
"    <p>",
"     Follow up testing after an abnormal mammogram is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/56/6018?source=see_link&amp;anchor=H8#H8\">",
"      \"Patient information: Common breast problems (Beyond the Basics)\", section on 'Abnormal mammogram'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Breast exam by your doctor or nurse",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your doctor or nurse might perform a breast exam on a regular basis as part of breast cancer screening. During the exam, the doctor or nurse will look at the breasts and then carefully feel both breasts and the area under both arms.",
"    </p>",
"    <p>",
"     Most expert groups recommend having a breast exam, along with a mammogram, starting at age 40 to 50.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Breast self-exam",
"     </span>",
"     &nbsp;&mdash;&nbsp;Breast self-exam is a way of finding changes in your own breasts. No study has shown that breast self-exam reduces the risk of dying from breast cancer. Nevertheless, some women feel that doing breast self-exam on a regular basis improves their ability to find changes that would otherwise not have been noticed. Many expert groups encourage breast self-awareness, which includes education about risk factors for breast cancer and what to do if a breast abnormality is detected. Women who want to perform breast self-exams should still continue to get regular mammograms and breast exams by a doctor or nurse because they are better screening tests.",
"    </p>",
"    <p>",
"     Instructions for performing a breast self-exam are provided here (",
"     <a class=\"graphic graphic_table graphicRef53792 \" href=\"mobipreview.htm?36/43/37563\">",
"      table 1",
"     </a>",
"     ). The best time to perform breast self-exam is about one week after your menstrual period ends, when the breasts are least lumpy. If you do not have menstrual periods, you can pick one day each month.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Breast MRI",
"     </span>",
"     &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) uses a strong magnet rather than x-rays to create a detailed image.",
"    </p>",
"    <p>",
"     Compared to mammograms, breast MRI:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Has more \"false positive\" findings (changes that are not breast cancer)",
"      </li>",
"      <li>",
"       May lead to more unnecessary biopsies in women who are not at high risk for breast cancer &nbsp;",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Breast MRI may be recommended, in addition to mammography, to help find breast cancer in young women with a high risk for developing breast cancer (such as those with a very strong family history or a breast cancer gene) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/40/36481/abstract/1\">",
"      1",
"     </a>",
"     ]. However, breast MRI is not recommended to screen for breast cancer in women who do not have a high risk of breast cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      BREAST CANCER SCREENING RECOMMENDATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      When to start mammograms",
"     </span>",
"     &nbsp;&mdash;&nbsp;All expert groups agree that women age 50 and older should have screening for breast cancer (including a mammogram and a breast exam). There is controversy about use of mammograms among women in their 40s because on average, breast cancer is less common in the 40s while the chances of having an abnormal mammogram that must be worked up are higher.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Some expert groups recommend starting mammograms at age 40 [",
"       <a class=\"abstract\" href=\"mobipreview.htm?35/40/36481/abstract/2\">",
"        2",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Other groups recommend that women between ages 40 to 49 talk to their doctor or nurse about the risks and benefits of mammograms. Your decision to have or delay mammograms between ages 40 to 49 should be based on your individual preferences and risk of breast cancer [",
"       <a class=\"abstract\" href=\"mobipreview.htm?35/40/36481/abstract/3\">",
"        3",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      How often to have a mammogram",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women who choose to have breast cancer screening beginning at age 40 are usually screened once per year until age 50.",
"      </li>",
"      <li>",
"       After age 50, most expert groups recommend breast cancer screening every one to two years, depending on the woman's individual risk of breast cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      When to stop mammograms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most expert groups recommend that women continue to get routine mammograms and clinical breast exams as long as the woman is expected to live at least 10 years. This is because the risk of developing breast cancer increases as women age. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/6/44134?source=see_link\">",
"      \"Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365167\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365174\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=see_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/19/2357?source=see_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/63/10227?source=see_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/62/6115?source=see_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/26/27043?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/62/11236?source=see_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/8/8321?source=see_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3492?source=see_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/59/6066?source=see_link\">",
"      Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365199\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/15/30963?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/56/6018?source=see_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/6/44134?source=see_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365211\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24825?source=see_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=see_link\">",
"      Screening for breast cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/pdq/screening/breast/Patient\">",
"      www.cancer.gov/cancertopics/pdq/screening/breast/Patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/mammography.html\">",
"      www.nlm.nih.gov/medlineplus/mammography.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/40/36481/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 25, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/40/36481?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36481/abstract/1\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36481/abstract/2\">",
"      Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36481/abstract/3\">",
"      Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:727.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_40_36481=[""].join("\n");
var outline_f35_40_36481=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BREAST CANCER SCREENING METHODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           BREAST CANCER SCREENING RECOMMENDATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/43/37563\" title=\"table 1\">",
"           Breast self-exam PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_40_36482="Biceps tendon anatomy";
var content_f35_40_36482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the biceps brachii muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36482=[""].join("\n");
var outline_f35_40_36482=null;
var title_f35_40_36483="Patient information: Diabetes and diet (The Basics)";
var content_f35_40_36483=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/52/37699\">",
"         Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/12/14531\">",
"         Patient information: Low blood sugar in people with diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/49/16147\">",
"         Patient information: Treatment for type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/58/28579\">",
"         Patient information: Using insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/60/6083\">",
"         Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/28/18886\">",
"         Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/8/9347\">",
"         Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/39/8817\">",
"         Patient information: High-fiber diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/63/4083\">",
"         Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/20/3397\">",
"         Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/32/31239\">",
"         Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diabetes and diet (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/diabetes-and-diet-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1478719001\">",
"      <span class=\"h1\">",
"       Why is diet important in diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diet is important, because it is part of diabetes treatment. Many people need to change what they eat and how much they eat to help treat their diabetes. It is important for people to treat their diabetes so that they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep their blood sugar at or near a normal level",
"       </li>",
"       <li>",
"        Prevent long-term problems, such as heart or kidney problems, that can happen in people with diabetes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Changing your diet can also help treat obesity, high blood pressure, and high cholesterol. These conditions can affect people with diabetes and can lead to future problems, such as heart attacks or strokes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478719008\">",
"      <span class=\"h1\">",
"       Who will work with me to change my diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will work with you to make a food plan to change your diet. He or she might also recommend that you work with a &ldquo;dietitian.&rdquo; A dietitian is an expert on food and eating.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478719015\">",
"      <span class=\"h1\">",
"       Must I eat at the same times every day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When and how often you should eat depends, in part, on the diabetes medicine that you take. For example, people who use a certain type of insulin or who take diabetes pills that increase insulin levels (called &ldquo;sulfonylureas&rdquo;) should eat meals at the same time each day. This helps prevent people from getting low blood sugar.",
"     </p>",
"     <p>",
"      People who use an insulin pump, insulin before each meal, or pills that improve the way insulin works (called &ldquo;",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/22/358?source=see_link\">",
"       metformin",
"      </a>",
"      &rdquo;) do not always have to eat meals at the same time. That&rsquo;s because people who use these treatments have a smaller chance of getting low blood sugar.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478719022\">",
"      <span class=\"h1\">",
"       What do I need to think about when planning what to eat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When planning what to eat, people with diabetes need to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Carbohydrates, proteins, and fats &ndash; Our bodies break down the food we eat into small pieces called carbohydrates, proteins, and fats. Carbohydrates, which are sugars that our bodies use for energy, can raise a person&rsquo;s blood sugar level. Your doctor, nurse, or dietitian will tell you how many carbohydrates you should eat at each meal or snack. Foods that have carbohydrates include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Bread, pasta, and rice",
"       </li>",
"       <li>",
"        Vegetables and fruits",
"       </li>",
"       <li>",
"        Dairy foods",
"       </li>",
"       <li>",
"        Foods with added sugar",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Calories &ndash; People need to eat a certain amount of calories each day to keep their weight the same. People who are overweight and want to lose weight need to eat fewer calories each day.",
"       </li>",
"       <li>",
"        Fiber &ndash; Eating foods with a lot of fiber can help control a person&rsquo;s blood sugar level.",
"       </li>",
"       <li>",
"        Cholesterol &ndash; People who have high cholesterol levels might need to reduce the amount of cholesterol they eat. Foods with a lot of cholesterol include red meat, whole milk, and egg yolks.",
"       </li>",
"       <li>",
"        Salt &ndash; People who have high blood pressure should not eat foods that contain a lot of salt (also called sodium). People with high blood pressure should also eat healthy foods, such as fruits, vegetables, and low-fat dairy foods.",
"       </li>",
"       <li>",
"        Alcohol &ndash; Having more than 1 drink (for women) or 2 drinks (for men) a day can raise blood sugar levels. Also, drinks that have fruit juice or soda in them can raise blood sugar levels.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478719029\">",
"      <span class=\"h1\">",
"       What can I do if I need to lose weight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you need to lose weight, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Exercise &ndash; Try to exercise for 30 minutes a day, most days of the week. Some people with diabetes need to change their medicine dose before they exercise. They might also need to check their blood sugar levels before and after exercising.",
"       </li>",
"       <li>",
"        Eat fewer calories &ndash; Your doctor, nurse, or dietitian can tell you how many calories you should eat each day in order to lose weight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you are worried about your weight, size, or shape, talk with your doctor, nurse, or dietitian so that he or she can help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478719036\">",
"      <span class=\"h1\">",
"       Can I eat the same foods as my family?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You do not need to eat special foods if you have diabetes. You and your family can eat the same foods. Changing your diet is mostly about eating healthy foods and not eating too much.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478719043\">",
"      <span class=\"h1\">",
"       What are the other parts of diabetes treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The other parts of diabetes treatment are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Exercise",
"       </li>",
"       <li>",
"        Medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with diabetes need to learn how to match their diet and exercise with their medicine dose. For example, people who use insulin might need to choose the dose of insulin they give themselves. To choose their dose, they need to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What they plan to eat at the next meal",
"       </li>",
"       <li>",
"        How much exercise they plan to do",
"       </li>",
"       <li>",
"        What their blood sugar level is",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the diet and exercise do not match the medicine dose, a person&rsquo;s blood sugar level can get too low or too high. Blood sugar levels that are too low or too high can cause problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478719050\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=see_link\">",
"       Patient information: Using insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=see_link\">",
"       Patient information: Treatment for type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/12/14531?source=see_link\">",
"       Patient information: Low blood sugar in people with diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=see_link\">",
"       Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"       Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/32/31239?source=see_link\">",
"       Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/60/6083?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"       Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=see_link\">",
"       Patient information: High-fiber diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/40/36483?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15730 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36483=[""].join("\n");
var outline_f35_40_36483=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719001\">",
"      Why is diet important in diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719008\">",
"      Who will work with me to change my diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719015\">",
"      Must I eat at the same times every day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719022\">",
"      What do I need to think about when planning what to eat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719029\">",
"      What can I do if I need to lose weight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719036\">",
"      Can I eat the same foods as my family?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719043\">",
"      What are the other parts of diabetes treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478719050\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/60/6083?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=related_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/12/14531?source=related_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=related_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/32/31239?source=related_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_40_36484="Reproductive and sexual dysfunction in uremic women";
var content_f35_40_36484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reproductive and sexual dysfunction in uremic women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36484/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/40/36484/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disturbances in menstruation, fertility, and sexual dysfunction are commonly encountered in women with chronic renal failure, usually leading to amenorrhea by the time the patient reaches end-stage renal disease. The menstrual cycle typically remains irregular with scanty flow after the initiation of maintenance dialysis, although normal menses are restored in some women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In others, menorrhagia develops, sometimes leading to significant blood loss and increased transfusion requirements.",
"   </p>",
"   <p>",
"    The major menstrual cycle abnormality in uremic women is",
"    <strong>",
"     anovulation",
"    </strong>",
"    , resulting in infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/6\">",
"     6",
"    </a>",
"    ]. Women receiving chronic dialysis also tend to experience decreased libido and reduced ability to reach orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/7-11\">",
"     7-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although rare, pregnancy can occur in women with advanced renal failure, but fetal wastage is markedly increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/8\">",
"     8",
"    </a>",
"    ]. Some residual renal function is usually present in the infrequent pregnancy that can be carried to term. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL MENSTRUAL CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal menstrual cycle is divided into a",
"    <strong>",
"     follicular",
"    </strong>",
"    or proliferative phase and a",
"    <strong>",
"     luteal",
"    </strong>",
"    or secretory phase. During the follicular phase, gradually increasing secretion of follicle stimulating hormone (FSH) causes recruitment and maturation of a single ovum and increasing secretion of estradiol. When the estradiol concentration reaches a sufficiently high level, it stimulates a sudden increase in luteinizing hormone (LH) secretion, thereby causing the release of a mature ovum; this is called ovulation. LH then stimulates the remainder of the follicle, called the corpus luteum, to secrete both estradiol and progesterone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HORMONAL DISTURBANCES IN UREMIC PREMENOPAUSAL WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect determination of ovulation suggests that anovulatory cycles are the rule in uremic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/12\">",
"     12",
"    </a>",
"    ]. This conclusion is supported by the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of progestational effect on the endometrium, as determined by biopsy.",
"     </li>",
"     <li>",
"      Absence of an increase in basal body temperature during the expected luteal phase of the menstrual cycle. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26724?source=see_link\">",
"       \"Evaluation of the menstrual cycle and timing of ovulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Absence of the preovulatory peak in LH and estradiol concentrations. The failure of LH to rise in part reflects a disturbance in the positive estradiol feedback pathway, since the administration of exogenous estrogen to mimic the preovulatory surge in estradiol fails to stimulate LH release [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/12\">",
"       12",
"      </a>",
"      ]. In contrast, feedback inhibition of gonadotropin release by low doses of estradiol remains intact. This can be illustrated by the ability of the antiestrogen",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      to enhance LH and FSH secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prolactin and galactorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with chronic renal failure commonly have elevated circulating prolactin concentrations and galactorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/14\">",
"     14",
"    </a>",
"    ] due to increased secretion and decreased metabolic clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/15\">",
"     15",
"    </a>",
"    ]. The hypersecretion of prolactin in this setting appears to be relatively autonomous, as it is resistant to maneuvers designed to stimulate or inhibit its release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/16\">",
"     16",
"    </a>",
"    ]. Similar observations have been made in uremic males. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20951?source=see_link\">",
"     \"Sexual dysfunction in uremic men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The elevated prolactin levels may impair hypothalamic-pituitary function and contribute to sexual dysfunction and galactorrhea in these patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     Bromocriptine",
"    </a>",
"    treatment corrects the hyperprolactinemia in these patients but does not restore normal menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/12,14\">",
"     12,14",
"    </a>",
"    ], thereby suggesting that other mechanisms are involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment goals for uremic women with sexual dysfunction include maximizing the delivered dose of dialysis, discontinuing culprit medications (if possible), and correcting the anemia of chronic renal failure. More specific measures are utilized based upon the underlying disorder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complaint (",
"    <a class=\"graphic graphic_figure graphicRef53114 \" href=\"mobipreview.htm?39/12/40142\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oligomenorrhea or amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of a progestin (eg, 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    ) for 10 days each month to women with renal failure and chronic anovulation but a serum estradiol concentration within the normal range for the follicular phase of the menstrual cycle, will result in menses. This treatment may also reduce the chance that the endometrial hyperplasia that results from chronic stimulation of the endometrium with estradiol but not progesterone will lead to a predisposition to endometrial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronic administration of a progestin frequently terminates menstrual flow in a woman with metrorrhagia; rarely, however, such patients will require a hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Regular menses",
"    </span>",
"    &nbsp;&mdash;&nbsp;While pregnancy can rarely occur spontaneously in women on chronic dialysis, restoration of fertility as a therapeutic goal should be discouraged. In comparison, the abnormalities in ovulation can usually be reversed and successful pregnancy achieved in women with a well-functioning renal transplant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .) Uremic women who are menstruating normally should be encouraged to use birth control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Decreased libido",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of studies exist concerning the therapy of decreased libido and sexual function in uremic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/5,19-21\">",
"     5,19-21",
"    </a>",
"    ]. In one of the largest studies, women from 27 dialysis units in Europe and South America were assessed using a 19-item questionnaire (the Female Sexual Function Index) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/19\">",
"     19",
"    </a>",
"    ]. Only 659 of 1472 women completed the questionnaire. Of the 659 women, sexual dysfunction was reported by 555 (84 percent) and was independently associated with age, symptoms of depression, less education, menopause and diuretic therapy. Nearly all women who did not have a partner and were not wait-listed for a kidney transplant reported sexual dysfunction. The generalizability of this study to all women on dialysis is somewhat limited by the low response rate. In addition, the observational nature of the study prevents conclusions regarding causality; as an example, the use of diuretics was likely just a marker for comorbid conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amenorrheic dialysis patients may have low estradiol levels; this may lead to vaginal atrophy and dryness, thereby resulting in discomfort during intercourse. Such patients may benefit from local estrogen therapy or vaginal lubricants. Successful transplantation is clearly the most effective means to restore normal sexual desire in women with chronic renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional possible therapies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although not well studied, the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      may help restore sexual function in those with hyperprolactinemia.",
"     </li>",
"     <li>",
"      Estrogen supplementation may improve sexual function in women with low circulating levels of estradiol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36484/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8618388\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disturbances in menstruation, fertility, and sexual dysfunction are common in women with chronic renal failure. Most women have amenorrhea by the time they reach end-stage renal disease, although menorrhagia leading to significant blood loss and increased transfusion requirements develops in some women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major menstrual cycle abnormality in uremic women is",
"      <strong>",
"       anovulation",
"      </strong>",
"      . Women receiving chronic dialysis also tend to experience decreased libido and reduced ability to reach orgasm. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Hormonal disturbances in uremic premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexual dysfunction is due in part to elevated circulating prolactin concentrations, which may impair hypothalamic-pituitary function. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prolactin and galactorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial treatment goals for uremic women with sexual dysfunction include maximizing the delivered dose of dialysis, discontinuing culprit medications (if possible), and correcting the anemia of chronic renal failure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The administration of a progestin (eg, 5 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      ) for 10 days each month to women with renal failure and chronic anovulation but normal serum estradiol will result in menses. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased libido may be caused in part by low estradiol levels which leads vaginal atrophy and dryness resulting in discomfort during intercourse. Such patients may benefit from local estrogen therapy or vaginal lubricants. Successful transplantation is clearly the most effective means to restore normal sexual desire in women with chronic renal failure. Other therapies",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      for those with hyperprolactinemia, and estrogen supplementation for women with low circulating levels of estradiol. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Decreased libido'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/1\">",
"      Holley JL, Schmidt RJ, Bender FH, et al. Gynecologic and reproductive issues in women on dialysis. Am J Kidney Dis 1997; 29:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/2\">",
"      Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/3\">",
"      Palmer, BF. Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Renal Rep Therapy; 2003; 10:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/4\">",
"      Matuszkiewicz-Rowinska J, Sk&oacute;rzewska K, Radowicki S, et al. Endometrial morphology and pituitary-gonadal axis dysfunction in women of reproductive age undergoing chronic haemodialysis--a multicentre study. Nephrol Dial Transplant 2004; 19:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/5\">",
"      Peng YS, Chiang CK, Kao TW, et al. Sexual dysfunction in female hemodialysis patients: a multicenter study. Kidney Int 2005; 68:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/6\">",
"      Zingraff J, Jungers P, P&eacute;lissier C, et al. Pituitary and ovarian dysfunctions in women on haemodialysis. Nephron 1982; 30:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/7\">",
"      Toorians AW, Janssen E, Laan E, et al. Chronic renal failure and sexual functioning: clinical status versus objectively assessed sexual response. Nephrol Dial Transplant 1997; 12:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/8\">",
"      Hou S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis 1999; 33:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/9\">",
"      Steele TE, Wuerth D, Finkelstein S, et al. Sexual experience of the chronic peritoneal dialysis patient. J Am Soc Nephrol 1996; 7:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/10\">",
"      Diemont WL, Vruggink PA, Meuleman EJ, et al. Sexual dysfunction after renal replacement therapy. Am J Kidney Dis 2000; 35:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/11\">",
"      Finkelstein FO, Shirani S, Wuerth D, Finkelstein SH. Therapy Insight: sexual dysfunction in patients with chronic kidney disease. Nat Clin Pract Nephrol 2007; 3:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/12\">",
"      Lim VS, Henriquez C, Sievertsen G, Frohman LA. Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med 1980; 93:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/13\">",
"      Swamy AP, Woolf PD, Cestero RV. Hypothalamic-pituitary-ovarian axis in uremic women. J Lab Clin Med 1979; 93:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/14\">",
"      G&oacute;mez F, de la Cueva R, Wauters JP, Lemarchand-B&eacute;raud T. Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin. Am J Med 1980; 68:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/15\">",
"      Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 1980; 50:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/16\">",
"      Hochstetler LA, Flanigan MJ, Lim VS. Abnormal endocrine tests in a hemodialysis patient. J Am Soc Nephrol 1994; 4:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/17\">",
"      Ginsburg, ES, Owen, WF. Reproductive endocrinology and pregnancy in women on hemodialysis. Semin Dial 1993; 6:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/18\">",
"      Rice GG. Hypermenorrhea in the young hemodialysis patient. Am J Obstet Gynecol 1973; 116:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/19\">",
"      Strippoli GF, Collaborative Depression and Sexual Dysfunction (CDS) in Hemodialysis Working Group, Vecchio M, et al. Sexual dysfunction in women with ESRD requiring hemodialysis. Clin J Am Soc Nephrol 2012; 7:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/20\">",
"      Seethala S, Hess R, Bossola M, et al. Sexual function in women receiving maintenance dialysis. Hemodial Int 2010; 14:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/21\">",
"      Yazici R, Altintepe L, Guney I, et al. Female sexual dysfunction in peritoneal dialysis and hemodialysis patients. Ren Fail 2009; 31:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/22\">",
"      Weisbord SD. Female sexual dysfunction in ESRD: an underappreciated epidemic? Clin J Am Soc Nephrol 2012; 7:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36484/abstract/23\">",
"      Matuszkiewicz-Rowi&ntilde;ska J, Sk&oacute;rzewska K, Radowicki S, et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 1999; 14:1238.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1975 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36484=[""].join("\n");
var outline_f35_40_36484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8618388\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL MENSTRUAL CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HORMONAL DISTURBANCES IN UREMIC PREMENOPAUSAL WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prolactin and galactorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oligomenorrhea or amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Regular menses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Decreased libido",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8618388\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1975|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/12/40142\" title=\"figure 1\">",
"      Rx sexual dys in uremic women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26724?source=related_link\">",
"      Evaluation of the menstrual cycle and timing of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20951?source=related_link\">",
"      Sexual dysfunction in uremic men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_40_36485="Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old";
var content_f35_40_36485=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"WHOInfantGrowthBoys_form\" name=\"WHOInfantGrowthBoys_form\" onkeydown=\"clrResults();\" onkeyup=\"WHOInfantGrowthBoys_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"WHOInfantGrowthBoys_fx(); minMaxCheck();\" onchange=\"WHOInfantGrowthBoys_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"WHOInfantGrowthBoys_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mo\">",
"              mo",
"             </option>",
"             <option value=\"12|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Length",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Length_param\" onblur=\"WHOInfantGrowthBoys_fx(); minMaxCheck();\" onchange=\"WHOInfantGrowthBoys_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Length_unit\" onchange=\"WHOInfantGrowthBoys_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"2.54|0|in\">",
"              in",
"             </option>",
"             <option value=\"100|0|m\">",
"              m",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Weight_param\" onblur=\"WHOInfantGrowthBoys_fx(); minMaxCheck();\" onchange=\"WHOInfantGrowthBoys_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"WHOInfantGrowthBoys_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|kg\">",
"              kg",
"             </option>",
"             <option value=\"0.45359237|0|lb\">",
"              lb",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Z Score Length",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Z_Score_Length_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Z Score Weight for Length",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Z_Score_Weight_for_Length_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Length Percentile",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Length_Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight for Length Percentile",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Weight_for_Length_Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"WHOInfantGrowthBoys_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option selected=\"selected\">",
"              1",
"             </option>",
"             <option>",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Assessment of Linear Growth",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Z-Score &gt; -2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         No stunting",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Z-Score &gt; -3 and &lt;= -2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Moderate stunting",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Z-Score &lt;= -3:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Severe stunting",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Assessment of Weight for Length",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr2_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Z-Score &gt; -2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         No wasting",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr2_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Z-Score &gt; -3 and &lt;= -2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Moderate wasting",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr2_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Z-Score &lt;= -3:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Severe wasting",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      Moderate malnutrition is defined as moderate stunting or wasting. Severe malnutrition is defined as severe stunting",
"or severe wasting, or edematous malnutrition. Patients with edematous malnutrition (Kwashiorkor) should be considered to",
"have severe malnutrition even if stunting or wasting z-scores are not in the severe range.",
"     </li>",
"     <li>",
"      This calculator uses measured recumbent Length for infants and toddlers from birth through 24 months of age,",
"and is not valid for standing height.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Infant Boys: Length for Age. World Health Organization 2008, Child Growth Standards: Methods and development.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Infant Boys: Weight for Length. World Health Organization 2008, Child Growth Standards: Methods and development.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36485=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.WHOInfantGrowthBoys_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function WHOInfantGrowthBoys_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.WHOInfantGrowthBoys_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Length_param.value.indexOf(',') >= 0){ Length_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Length_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Length_unit.options[Length_unit.selectedIndex].value.split('|');",
"Length = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"if(Age >= 0 && Age < 1){L = 1; M = 49.8842; S = 0.03795;};",
"if(Age >= 1 && Age < 2){L = 1; M = 54.7244; S = 0.03557;};",
"if(Age >= 2 && Age < 3){L = 1; M = 58.4249; S = 0.03424;};",
"if(Age >= 3 && Age < 4){L = 1; M = 61.4292; S = 0.03328;};",
"if(Age >= 4 && Age < 5){L = 1; M = 63.8860; S = 0.03257;};",
"if(Age >= 5 && Age < 6){L = 1; M = 65.9026; S = 0.03204;};",
"if(Age >= 6 && Age < 7){L = 1; M = 67.6236; S = 0.03165;};",
"if(Age >= 7 && Age < 8){L = 1; M = 69.1645; S = 0.03139;};",
"if(Age >= 8 && Age < 9){L = 1; M = 70.5994; S = 0.03124;};",
"if(Age >= 9 && Age < 10){L = 1; M = 71.9687; S = 0.03117;};",
"if(Age >= 10 && Age < 11){L = 1; M = 73.2812; S = 0.03118;};",
"if(Age >= 11 && Age < 12){L = 1; M = 74.5388; S = 0.03125;};",
"if(Age >= 12 && Age < 13){L = 1; M = 75.7488; S = 0.03137;};",
"if(Age >= 13 && Age < 14){L = 1; M = 76.9186; S = 0.03154;};",
"if(Age >= 14 && Age < 15){L = 1; M = 78.0497; S = 0.03174;};",
"if(Age >= 15 && Age < 16){L = 1; M = 79.1458; S = 0.03197;};",
"if(Age >= 16 && Age < 17){L = 1; M = 80.2113; S = 0.03222;};",
"if(Age >= 17 && Age < 18){L = 1; M = 81.2487; S = 0.03250;};",
"if(Age >= 18 && Age < 19){L = 1; M = 82.2587; S = 0.03279;};",
"if(Age >= 19 && Age < 20){L = 1; M = 83.2418; S = 0.03310;};",
"if(Age >= 20 && Age < 21){L = 1; M = 84.1996; S = 0.03342;};",
"if(Age >= 21 && Age < 22){L = 1; M = 85.1348; S = 0.03376;};",
"if(Age >= 22 && Age < 23){L = 1; M = 86.0477; S = 0.03410;};",
"if(Age >= 23 && Age < 24){L = 1; M = 86.9410; S = 0.03445;};",
"if(Age >= 24 && Age < 25){L = 1; M = 87.8161; S = 0.03479;};",
"Z_Score_Length =  (power((Length / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_Length_param.value = fixDP(Z_Score_Length, dp);",
"",
"",
"",
"if(Length >= 45 && Length < 45.5){L = -0.3521; M = 2.441; S = 0.09182;};",
"if(Length >= 45.5 && Length < 46){L = -0.3521; M = 2.5244; S = 0.09153;};",
"if(Length >= 46 && Length < 46.5){L = -0.3521; M = 2.6077; S = 0.09124;};",
"if(Length >= 46.5 && Length < 47){L = -0.3521; M = 2.6913; S = 0.09094;};",
"if(Length >= 47 && Length < 47.5){L = -0.3521; M = 2.7755; S = 0.09065;};",
"if(Length >= 47.5 && Length < 48){L = -0.3521; M = 2.8609; S = 0.09036;};",
"if(Length >= 48 && Length < 48.5){L = -0.3521; M = 2.948; S = 0.09007;};",
"if(Length >= 48.5 && Length < 49){L = -0.3521; M = 3.0377; S = 0.08977;};",
"if(Length >= 49 && Length < 49.5){L = -0.3521; M = 3.1308; S = 0.08948;};",
"if(Length >= 49.5 && Length < 50){L = -0.3521; M = 3.2276; S = 0.08919;};",
"if(Length >= 50 && Length < 50.5){L = -0.3521; M = 3.3278; S = 0.0889;};",
"if(Length >= 50.5 && Length < 51){L = -0.3521; M = 3.4311; S = 0.08861;};",
"if(Length >= 51 && Length < 51.5){L = -0.3521; M = 3.5376; S = 0.08831;};",
"if(Length >= 51.5 && Length < 52){L = -0.3521; M = 3.6477; S = 0.08801;};",
"if(Length >= 52 && Length < 52.5){L = -0.3521; M = 3.762; S = 0.08771;};",
"if(Length >= 52.5 && Length < 53){L = -0.3521; M = 3.8814; S = 0.08741;};",
"if(Length >= 53 && Length < 53.5){L = -0.3521; M = 4.006; S = 0.08711;};",
"if(Length >= 53.5 && Length < 54){L = -0.3521; M = 4.1354; S = 0.08681;};",
"if(Length >= 54 && Length < 54.5){L = -0.3521; M = 4.2693; S = 0.08651;};",
"if(Length >= 54.5 && Length < 55){L = -0.3521; M = 4.4066; S = 0.08621;};",
"if(Length >= 55 && Length < 55.5){L = -0.3521; M = 4.5467; S = 0.08592;};",
"if(Length >= 55.5 && Length < 56){L = -0.3521; M = 4.6892; S = 0.08563;};",
"if(Length >= 56 && Length < 56.5){L = -0.3521; M = 4.8338; S = 0.08535;};",
"if(Length >= 56.5 && Length < 57){L = -0.3521; M = 4.9796; S = 0.08507;};",
"if(Length >= 57 && Length < 57.5){L = -0.3521; M = 5.1259; S = 0.08481;};",
"if(Length >= 57.5 && Length < 58){L = -0.3521; M = 5.2721; S = 0.08455;};",
"if(Length >= 58 && Length < 58.5){L = -0.3521; M = 5.418; S = 0.0843;};",
"if(Length >= 58.5 && Length < 59){L = -0.3521; M = 5.5632; S = 0.08406;};",
"if(Length >= 59 && Length < 59.5){L = -0.3521; M = 5.7074; S = 0.08383;};",
"if(Length >= 59.5 && Length < 60){L = -0.3521; M = 5.8501; S = 0.08362;};",
"if(Length >= 60 && Length < 60.5){L = -0.3521; M = 5.9907; S = 0.08342;};",
"if(Length >= 60.5 && Length < 61){L = -0.3521; M = 6.1284; S = 0.08324;};",
"if(Length >= 61 && Length < 61.5){L = -0.3521; M = 6.2632; S = 0.08308;};",
"if(Length >= 61.5 && Length < 62){L = -0.3521; M = 6.3954; S = 0.08292;};",
"if(Length >= 62 && Length < 62.5){L = -0.3521; M = 6.5251; S = 0.08279;};",
"if(Length >= 62.5 && Length < 63){L = -0.3521; M = 6.6527; S = 0.08266;};",
"if(Length >= 63 && Length < 63.5){L = -0.3521; M = 6.7786; S = 0.08255;};",
"if(Length >= 63.5 && Length < 64){L = -0.3521; M = 6.9028; S = 0.08245;};",
"if(Length >= 64 && Length < 64.5){L = -0.3521; M = 7.0255; S = 0.08236;};",
"if(Length >= 64.5 && Length < 65){L = -0.3521; M = 7.1467; S = 0.08229;};",
"if(Length >= 65 && Length < 65.5){L = -0.3521; M = 7.2666; S = 0.08223;};",
"if(Length >= 65.5 && Length < 66){L = -0.3521; M = 7.3854; S = 0.08218;};",
"if(Length >= 66 && Length < 66.5){L = -0.3521; M = 7.5034; S = 0.08215;};",
"if(Length >= 66.5 && Length < 67){L = -0.3521; M = 7.6206; S = 0.08213;};",
"if(Length >= 67 && Length < 67.5){L = -0.3521; M = 7.737; S = 0.08212;};",
"if(Length >= 67.5 && Length < 68){L = -0.3521; M = 7.8526; S = 0.08212;};",
"if(Length >= 68 && Length < 68.5){L = -0.3521; M = 7.9674; S = 0.08214;};",
"if(Length >= 68.5 && Length < 69){L = -0.3521; M = 8.0816; S = 0.08216;};",
"if(Length >= 69 && Length < 69.5){L = -0.3521; M = 8.1955; S = 0.08219;};",
"if(Length >= 69.5 && Length < 70){L = -0.3521; M = 8.3092; S = 0.08224;};",
"if(Length >= 70 && Length < 70.5){L = -0.3521; M = 8.4227; S = 0.08229;};",
"if(Length >= 70.5 && Length < 71){L = -0.3521; M = 8.5358; S = 0.08235;};",
"if(Length >= 71 && Length < 71.5){L = -0.3521; M = 8.648; S = 0.08241;};",
"if(Length >= 71.5 && Length < 72){L = -0.3521; M = 8.7594; S = 0.08248;};",
"if(Length >= 72 && Length < 72.5){L = -0.3521; M = 8.8697; S = 0.08254;};",
"if(Length >= 72.5 && Length < 73){L = -0.3521; M = 8.9788; S = 0.08262;};",
"if(Length >= 73 && Length < 73.5){L = -0.3521; M = 9.0865; S = 0.08269;};",
"if(Length >= 73.5 && Length < 74){L = -0.3521; M = 9.1927; S = 0.08276;};",
"if(Length >= 74 && Length < 74.5){L = -0.3521; M = 9.2974; S = 0.08283;};",
"if(Length >= 74.5 && Length < 75){L = -0.3521; M = 9.401; S = 0.08289;};",
"if(Length >= 75 && Length < 75.5){L = -0.3521; M = 9.5032; S = 0.08295;};",
"if(Length >= 75.5 && Length < 76){L = -0.3521; M = 9.6041; S = 0.08301;};",
"if(Length >= 76 && Length < 76.5){L = -0.3521; M = 9.7033; S = 0.08307;};",
"if(Length >= 76.5 && Length < 77){L = -0.3521; M = 9.8007; S = 0.08311;};",
"if(Length >= 77 && Length < 77.5){L = -0.3521; M = 9.8963; S = 0.08314;};",
"if(Length >= 77.5 && Length < 78){L = -0.3521; M = 9.9902; S = 0.08317;};",
"if(Length >= 78 && Length < 78.5){L = -0.3521; M = 10.0827; S = 0.08318;};",
"if(Length >= 78.5 && Length < 79){L = -0.3521; M = 10.1741; S = 0.08318;};",
"if(Length >= 79 && Length < 79.5){L = -0.3521; M = 10.2649; S = 0.08316;};",
"if(Length >= 79.5 && Length < 80){L = -0.3521; M = 10.3558; S = 0.08313;};",
"if(Length >= 80 && Length < 80.5){L = -0.3521; M = 10.4475; S = 0.08308;};",
"if(Length >= 80.5 && Length < 81){L = -0.3521; M = 10.5405; S = 0.08301;};",
"if(Length >= 81 && Length < 81.5){L = -0.3521; M = 10.6352; S = 0.08293;};",
"if(Length >= 81.5 && Length < 82){L = -0.3521; M = 10.7322; S = 0.08284;};",
"if(Length >= 82 && Length < 82.5){L = -0.3521; M = 10.8321; S = 0.08273;};",
"if(Length >= 82.5 && Length < 83){L = -0.3521; M = 10.935; S = 0.0826;};",
"if(Length >= 83 && Length < 83.5){L = -0.3521; M = 11.0415; S = 0.08246;};",
"if(Length >= 83.5 && Length < 84){L = -0.3521; M = 11.1516; S = 0.08231;};",
"if(Length >= 84 && Length < 84.5){L = -0.3521; M = 11.2651; S = 0.08215;};",
"if(Length >= 84.5 && Length < 85){L = -0.3521; M = 11.3817; S = 0.08198;};",
"if(Length >= 85 && Length < 85.5){L = -0.3521; M = 11.5007; S = 0.08181;};",
"if(Length >= 85.5 && Length < 86){L = -0.3521; M = 11.6218; S = 0.08163;};",
"if(Length >= 86 && Length < 86.5){L = -0.3521; M = 11.7444; S = 0.08145;};",
"if(Length >= 86.5 && Length < 87){L = -0.3521; M = 11.8678; S = 0.08128;};",
"if(Length >= 87 && Length < 87.5){L = -0.3521; M = 11.9916; S = 0.08111;};",
"if(Length >= 87.5 && Length < 88){L = -0.3521; M = 12.1152; S = 0.08096;};",
"if(Length >= 88 && Length < 88.5){L = -0.3521; M = 12.2382; S = 0.08082;};",
"if(Length >= 88.5 && Length < 89){L = -0.3521; M = 12.3603; S = 0.08069;};",
"if(Length >= 89 && Length < 89.5){L = -0.3521; M = 12.4815; S = 0.08058;};",
"if(Length >= 89.5 && Length < 90){L = -0.3521; M = 12.6017; S = 0.08048;};",
"if(Length >= 90 && Length < 90.5){L = -0.3521; M = 12.7209; S = 0.08041;};",
"if(Length >= 90.5 && Length < 91){L = -0.3521; M = 12.8392; S = 0.08034;};",
"if(Length >= 91 && Length < 91.5){L = -0.3521; M = 12.9569; S = 0.0803;};",
"if(Length >= 91.5 && Length < 92){L = -0.3521; M = 13.0742; S = 0.08026;};",
"if(Length >= 92 && Length < 92.5){L = -0.3521; M = 13.191; S = 0.08025;};",
"if(Length >= 92.5 && Length < 93){L = -0.3521; M = 13.3075; S = 0.08025;};",
"if(Length >= 93 && Length < 93.5){L = -0.3521; M = 13.4239; S = 0.08026;};",
"if(Length >= 93.5 && Length < 94){L = -0.3521; M = 13.5404; S = 0.08029;};",
"if(Length >= 94 && Length < 94.5){L = -0.3521; M = 13.6572; S = 0.08034;};",
"if(Length >= 94.5 && Length < 95){L = -0.3521; M = 13.7746; S = 0.0804;};",
"if(Length >= 95 && Length < 95.5){L = -0.3521; M = 13.8928; S = 0.08047;};",
"if(Length >= 95.5 && Length < 96){L = -0.3521; M = 14.012; S = 0.08056;};",
"if(Length >= 96 && Length < 96.5){L = -0.3521; M = 14.1325; S = 0.08067;};",
"if(Length >= 96.5 && Length < 97){L = -0.3521; M = 14.2544; S = 0.08078;};",
"if(Length >= 97 && Length < 97.5){L = -0.3521; M = 14.3782; S = 0.08092;};",
"if(Length >= 97.5 && Length < 98){L = -0.3521; M = 14.5038; S = 0.08106;};",
"if(Length >= 98 && Length < 98.5){L = -0.3521; M = 14.6316; S = 0.08122;};",
"if(Length >= 98.5 && Length < 99){L = -0.3521; M = 14.7614; S = 0.08139;};",
"if(Length >= 99 && Length < 99.5){L = -0.3521; M = 14.8934; S = 0.08157;};",
"if(Length >= 99.5 && Length < 100){L = -0.3521; M = 15.0275; S = 0.08177;};",
"if(Length >= 100 && Length < 100.5){L = -0.3521; M = 15.1637; S = 0.08198;};",
"if(Length >= 100.5 && Length < 101){L = -0.3521; M = 15.3018; S = 0.0822;};",
"if(Length >= 101 && Length < 101.5){L = -0.3521; M = 15.4419; S = 0.08243;};",
"if(Length >= 101.5 && Length < 102){L = -0.3521; M = 15.5838; S = 0.08267;};",
"if(Length >= 102 && Length < 102.5){L = -0.3521; M = 15.7276; S = 0.08292;};",
"if(Length >= 102.5 && Length < 103){L = -0.3521; M = 15.8732; S = 0.08317;};",
"if(Length >= 103 && Length < 103.5){L = -0.3521; M = 16.0206; S = 0.08343;};",
"if(Length >= 103.5 && Length < 104){L = -0.3521; M = 16.1697; S = 0.0837;};",
"if(Length >= 104 && Length < 104.5){L = -0.3521; M = 16.3204; S = 0.08397;};",
"if(Length >= 104.5 && Length < 105){L = -0.3521; M = 16.4728; S = 0.08425;};",
"if(Length >= 105 && Length < 105.5){L = -0.3521; M = 16.6268; S = 0.08453;};",
"if(Length >= 105.5 && Length < 106){L = -0.3521; M = 16.7826; S = 0.08481;};",
"if(Length >= 106 && Length < 106.5){L = -0.3521; M = 16.9401; S = 0.0851;};",
"if(Length >= 106.5 && Length < 107){L = -0.3521; M = 17.0995; S = 0.08539;};",
"if(Length >= 107 && Length < 107.5){L = -0.3521; M = 17.2607; S = 0.08568;};",
"if(Length >= 107.5 && Length < 108){L = -0.3521; M = 17.4237; S = 0.08599;};",
"if(Length >= 108 && Length < 108.5){L = -0.3521; M = 17.5885; S = 0.08629;};",
"if(Length >= 108.5 && Length < 109){L = -0.3521; M = 17.7553; S = 0.0866;};",
"if(Length >= 109 && Length < 109.5){L = -0.3521; M = 17.9242; S = 0.08691;};",
"if(Length >= 109.5 && Length < 110){L = -0.3521; M = 18.0954; S = 0.08723;};",
"if(Length >= 110 && Length < 110.5){L = -0.3521; M = 18.2689; S = 0.08755;};",
"Z_Score_Weight_for_Length =  (power((Weight / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_Weight_for_Length_param.value = fixDP(Z_Score_Weight_for_Length, dp);",
"",
"",
"",
"Length_Percentile =  ZtoPercentile(Z_Score_Length);",
"",
"if (doCalc) Length_Percentile_param.value = fixDP(Length_Percentile, dp);",
"",
"",
"",
"Weight_for_Length_Percentile =  ZtoPercentile(Z_Score_Weight_for_Length);",
"",
"if (doCalc) Weight_for_Length_Percentile_param.value = fixDP(Weight_for_Length_Percentile, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Z_Score_Length > -2){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Z_Score_Length > -3) && (Z_Score_Length <= -2)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Z_Score_Length <= -3){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Z_Score_Length > -2){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Z_Score_Length > -3) && (Z_Score_Length <= -2)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Z_Score_Length <= -3){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"if (Z_Score_Weight_for_Length > -2){ document.getElementById('rr2_1').bgColor = \"#cccccc\";",
"}",
"if ((Z_Score_Weight_for_Length > -3) && (Z_Score_Weight_for_Length <= -2)){ document.getElementById('rr2_2').bgColor = \"#cccccc\";",
"}",
"if (Z_Score_Weight_for_Length <= -3){ document.getElementById('rr2_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantGrowthBoys_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 24) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 24 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Length_param.value && Length < 45) {",
"Length = 0;",
"Length_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Length is 45 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Length_param.value && Length > 110) {",
"Length_param.value = \"\";",
"clrResults();",
"Length = 0;",
"doCalc = false;",
"alert(\"The maximum value for Length is 110 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight < 1) {",
"Weight = 0;",
"Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Weight is 1 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight > 25) {",
"Weight_param.value = \"\";",
"clrResults();",
"Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Weight is 25 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantGrowthBoys_form){",
"",
"Z_Score_Length_param.value = '';",
"Z_Score_Weight_for_Length_param.value = '';",
"Length_Percentile_param.value = '';",
"Weight_for_Length_Percentile_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr2_1').bgColor = \"\";",
"document.getElementById('rr2_2').bgColor = \"\";",
"document.getElementById('rr2_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f35_40_36485=null;
var title_f35_40_36486="Treatment of brain metastases in poor prognosis patients";
var content_f35_40_36486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of brain metastases in poor prognosis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36486/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36486/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36486/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36486/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36486/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36486/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36486/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/40/36486/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastases are the most common intracranial tumor in adults, accounting for significantly more than one-half of all intracranial tumors. The primary approaches to the treatment of brain metastases include whole brain radiation therapy (WBRT), surgery, and stereotactic radiosurgery (SRS).",
"   </p>",
"   <p>",
"    Analysis of large series of patients with brain metastases has identified those factors that predict a poor response to treatment and relatively short survival. The key prognostic determinants and the management of patients with a poor prognosis will be reviewed here.",
"   </p>",
"   <p>",
"    The etiology, clinical manifestations, and diagnosis of brain metastases and the treatment of patients with a favorable prognosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551955440\">",
"    <span class=\"h1\">",
"     FAVORABLE VERSUS POOR PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival of patients who receive supportive care and are treated only with corticosteroids is approximately one to two months. The use of WBRT in large series increased the average survival from three to six months, and larger gains were seen in carefully selected subsets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551955447\">",
"    <span class=\"h2\">",
"     Recursive partitioning analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key parameters that determine survival after the diagnosis of brain metastases are performance status, the extent of extracranial disease, and age. The importance of these factors in determining outcome was illustrated by the use of recursive partitioning analysis (RPA) to analyze prognostic factors in 1200 patients from three Radiation Therapy Oncology Group (RTOG) brain metastases trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three prognostic classes were identified and the outcome correlated with median survival (",
"    <a class=\"graphic graphic_table graphicRef77561 \" href=\"mobipreview.htm?7/63/8187\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class 1 - The best prognosis was seen in patients who had a Karnofsky performance score 70 or higher (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ), were less than 65 years of age with a controlled primary tumor, and had no extracranial metastases. Median survival was 7.1 months. These patients are considered to have a",
"      <strong>",
"       favorable prognosis",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      Class 3 - Patients with a Karnofsky performance score less than 70 constituted the worst prognostic subset and had a median survival of 2.3 months. This group is considered to have a",
"      <strong>",
"       poor prognosis",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      Class 2 - This intermediate prognosis group included those with a Karnofsky performance score 70 or higher, but with other unfavorable characteristics. Median survival was 4.2 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients may be classified either as favorable or poor prognosis, depending largely upon the likelihood of controlling systemic disease.",
"   </p>",
"   <p>",
"    These results were subsequently validated in another RTOG trial that included 445 patients with brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/6\">",
"     6",
"    </a>",
"    ]. The median survival was 6.2 months for class 1 patients and 3.8 months for those in class 2.",
"   </p>",
"   <p>",
"    In the original RTOG analysis, approximately 20, 65, and 15 percent of the patients were in classes 1, 2, and 3, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the trials used for this analysis excluded patients with small cell lung cancer (SCLC), a subsequent analysis of 154 patients with brain metastases from SCLC confirmed the validity of RPA in this population as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551955454\">",
"    <span class=\"h2\">",
"     Diagnosis-specific graded prognostic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival results following treatment for brain metastases are highly heterogeneous and depend in part upon the primary tumor. This observation led to a proposal for diagnosis-specific graded prognostic assessment (DS-GPA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DS-GPA proposal was based upon an analysis of 4259 patients with newly diagnosed brain metastases treated between 1985 and 2007. Multivariate analysis of patients in this database, using the same criteria as in the RPA analysis, plus the primary diagnosis, led to the establishment of separate criteria for patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, renal cell carcinoma, breast cancer, and gastrointestinal cancer (",
"    <a class=\"graphic graphic_table graphicRef65322 \" href=\"mobipreview.htm?18/13/18654\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For patients with NSCLC or SCLC, all of the factors that entered into the RPA classification scheme retained their statistical significance. For patients with melanoma or RCC, only the Karnofsky performance score and number of brain metastases were statistically significant factors, while for those with breast cancer or a gastrointestinal primary, the Karnofsky performance score was the only statistically significant prognostic factor.",
"   </p>",
"   <p>",
"    For each of these disease categories, there was a statistically significant survival gradient with improvement in overall survival with a better DS-GPA score. These criteria provide improved prognostic information that may be useful patient management as well as clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551955603\">",
"    <span class=\"h2\">",
"     Poor prognosis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because patients with a poor prognosis have such a short expected survival, aggressive treatment generally is not warranted. For this group, WBRT is the preferred approach if active treatment is indicated, while SRS and surgery are generally reserved for patients with a relatively favorable prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible exception to this approach is when the poor performance status is due exclusively to the brain metastases. At least one study has suggested that aggressive treatment with SRS may be associated with improved survival when brain metastases are responsible for the poor performance status and are not accompanied by extracerebral disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Stereotactic radiosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WBRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main goal of WBRT is to improve neurologic deficits caused by the metastases and surrounding edema and to prevent any further deterioration of neurologic function. The extent of improvement after WBRT is directly related to the time from diagnosis to radiation therapy, and early treatment is generally associated with a better outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall response rate to WBRT ranges from 50 to 85 percent in various studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. The outcomes after WBRT can be illustrated by two large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of 183 patients, neurologic symptoms such as headache improved in 74 percent, two-thirds of whom maintained the improvement for the duration of their lives or for at least nine months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/12\">",
"       12",
"      </a>",
"      ]. Cranial nerve deficits improved in approximately 40 percent of patients.",
"     </li>",
"     <li>",
"      When response was assessed by CT scan in 108 patients with 336 metastatic lesions, 59 percent of lesions responded (24 percent complete and 35 percent partial responses) to treatment with 30 Gy in 10 fractions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/13\">",
"       13",
"      </a>",
"      ]. Responses were common in patients with small cell lung cancer, breast cancer, and squamous cell carcinoma, and infrequent with radioresistant tumors (eg, melanoma, renal cell carcinoma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most patients, overall survival is likely to be determined by the activity and extent of extracranial disease, not by the success of treatment in controlling brain metastases. Survival of patients who are not treated or are treated with corticosteroids alone is approximately one to two months; median survival is increased to three to six months with WBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/4,11,15,16\">",
"     4,11,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dose and fractionation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Radiation Therapy Oncology Group (RTOG) conducted a series of randomized trials to determine the optimal dose and fractionation schedule for WBRT in patients with brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/14,17,18\">",
"     14,17,18",
"    </a>",
"    ]. Patients were assigned to 40 Gy in four weeks, 40 Gy in three weeks, 30 Gy in three weeks, 30 Gy in two weeks, or 20 Gy in one week. The overall response rate (75 to 80 percent for symptom palliation) and median survival (15 to 18 weeks) were equivalent in all arms of these studies. Patients treated with larger fractions over a shorter time responded more quickly, but the duration of the clinical response and the time to progression were similar in all treatment arms. Brain metastases caused death in 40 percent of patients.",
"   </p>",
"   <p>",
"    Subsequent RTOG trials exploring the use of ultrarapid fractionation schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/19\">",
"     19",
"    </a>",
"    ], dose escalation in favorable prognosis subgroups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/20\">",
"     20",
"    </a>",
"    ], accelerated fractionation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/21\">",
"     21",
"    </a>",
"    ], and the use of radiosensitizers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/4,22,23\">",
"     4,22,23",
"    </a>",
"    ] failed to show any benefit over conventional radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used regimen is a total dose of 30 Gy in 10 daily fractions of 3 Gy. The decision in an individual case depends upon the severity of CNS symptoms, the extent of systemic disease, and physician preference.",
"   </p>",
"   <p>",
"    The dose and fractionation schedule should take into account the overall clinical status of the patient to maximize symptom palliation and minimize the risk of long-term complications. For patients with a relatively poor prognosis, we use 30 Gy in 3 Gy daily fractions. In contrast, those with a more favorable prognosis may be treated with prolonged fractionation to decrease the likelihood of late CNS toxicity. In these patients, we use a higher total dose in smaller fractions (eg, 40 to 45 Gy in 1.8 to 2.0 Gy daily fractions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxicity associated with WBRT is generally mild and self limited. These acute toxicities are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of cranial irradiation\", section on 'Acute reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebral edema may be induced or worsened after the initiation of radiation. As a result, WBRT should be preceded by corticosteroid therapy for at least 48 hours if there is evidence of significant edema and mass effect, regardless of the dose and fractionation schedule. In these patients, corticosteroids should be continued throughout the course of radiation and then the dose decreased as tolerated. Patients with small metastases and no mass effect may not need corticosteroids. The recommended steroid regimen is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Dose and schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Late toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients treated with WBRT for brain metastases have a limited survival, patients with longer survival may have debilitating late complications. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukoencephalopathy and brain atrophy, leading to neurocognitive deterioration and dementia",
"     </li>",
"     <li>",
"      Radiation necrosis, with symptoms related to the site of necrosis",
"     </li>",
"     <li>",
"      Normal pressure hydrocephalus, causing cognitive, gait and bladder dysfunction",
"     </li>",
"     <li>",
"      Neuroendocrine dysfunction, most commonly hypothyroidism",
"     </li>",
"     <li>",
"      Cerebrovascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk for late complications is related to the total radiation dose, fraction size, patient age, extent of disease, and neurologic impairment at presentation. Delayed complications of WBRT and neuroprotective strategies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"     \"Complications of cranial irradiation\", section on 'Late reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H1473216#H1473216\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Neuroprotective strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recurrent brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who recur within the CNS also have progressive extracranial disease, and only a small fraction of patients require retreatment. However, when the patient's overall condition is satisfactory, possible options include surgery, SRS, reirradiation, as well as systemic therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Reirradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retreatment with WBRT or partial brain reirradiation may provide some benefit for carefully selected patients who are not candidates for surgery or SRS. Several retrospective studies have reported clinical response rates of 42 to 75 percent and median survival of 3.5 to 5 months from the time of reirradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. There is no consensus on dose fractionation; dosing in these studies ranged from 8 Gy in two weeks to 30.6 Gy in three weeks with a median of approximately 20 Gy in two weeks.",
"   </p>",
"   <p>",
"    It is not known how early after the initial course of radiation therapy reirradiation can be administered. We suggest that reirradiation should be considered for patients who experience neurologic deterioration four or more months after a satisfactory response to the initial course of WBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36486/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reirradiation is likely to exceed the brain's tolerance and may result in delayed toxicity if the patient survives long enough. However, the risk of symptomatic late radiation-induced neurotoxicity must be weighed against short-term symptom palliation in patients with a limited life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Surgery or SRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery and SRS can have a role in the treatment of patients with recurrent brain metastases, primarily when systemic disease is well controlled. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main role for systemic chemotherapy in treating brain metastases in poor prognosis patients is for the management of progressive or recurrent disease, when further WBRT and radiosurgery are not feasible. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/217?source=see_link\">",
"     \"Systemic therapy for brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SYMPTOM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with brain metastases is similar to the approach used in those with primary brain tumors. Key components include the control of peritumoral edema and increased intracranial pressure with corticosteroids, the treatment of seizures, and the management of venous thromboembolic disease. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link\">",
"     \"Seizures in patients with primary and metastatic brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/12/19650?source=see_link\">",
"       \"Patient information: Brain metastases (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with brain metastases who have a poor performance status, widespread or uncontrolled systemic disease or extensive intracranial metastases have a poor prognosis. Treatment of brain metastases in these patients focuses on control of symptoms from the brain metastases and maintenance of neurologic function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      WBRT &mdash; We recommend WBRT for specific treatment of brain metastases (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'WBRT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although no dose fractionation schedule has demonstrated superiority, we suggest a total dose of 30 Gy in 10 fractions for most patients, to achieve a balance between the need for quick relief of symptoms versus the risk of late toxicity (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A higher dose with slower fractionation (eg, 40 to 45 Gy in 20 to 25 fractions) may be preferred in patients thought to have a longer life expectancy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dose and fractionation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptom management &mdash; We recommend medical management with corticosteroids to control peritumoral edema. Treatment for other tumor-related complications (eg, seizures, venous thromboembolic disease) may also be required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link\">",
"       \"Seizures in patients with primary and metastatic brain tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/1\">",
"      Posner JB. Management of brain metastases. Rev Neurol (Paris) 1992; 148:477.",
"     </a>",
"    </li>",
"    <li>",
"     Sawaya R, Bindal RK. Metastatic brain tumors. In: Brain Tumors, Kaye AH, Laws ER (Eds), Churchill Livingstone, Edinburgh 1995. p.923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/3\">",
"      Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr 1983; 103:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/4\">",
"      Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park) 1999; 13:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/5\">",
"      Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/6\">",
"      Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000; 47:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/7\">",
"      Videtic GM, Adelstein DJ, Mekhail TM, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases. Int J Radiat Oncol Biol Phys 2007; 67:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/8\">",
"      Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/9\">",
"      Chernov MF, Nakaya K, Izawa M, et al. Outcome after radiosurgery for brain metastases in patients with low Karnofsky performance scale (KPS) scores. Int J Radiat Oncol Biol Phys 2007; 67:1492.",
"     </a>",
"    </li>",
"    <li>",
"     Loeffler JS. Metastatic brain cancer. In: Cancer: Principles and Practice of Oncology, Devita VT, Hellman S, Rosenberg SA (Eds), JB Lippincott, Philadelphia 1997. p.2523.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/11\">",
"      Sneed PK, Larson DA, Wara WM. Radiotherapy for cerebral metastases. Neurosurg Clin N Am 1996; 7:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/12\">",
"      Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980; 7:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/13\">",
"      Nieder C, Berberich W, Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 1997; 39:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/14\">",
"      Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/15\">",
"      Patchell, R. Brain metastases. Handbook of Neurology 1997; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/16\">",
"      Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981; 48:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/17\">",
"      Vermeulen SS. Whole brain radiotherapy in the treatment of metastatic brain tumors. Semin Surg Oncol 1998; 14:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/18\">",
"      Berk L. An overview of radiotherapy trials for the treatment of brain metastases. Oncology (Williston Park) 1995; 9:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/19\">",
"      Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/20\">",
"      Kurtz JM, Gelber R, Brady LW, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/21\">",
"      Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997; 39:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/22\">",
"      Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 1991; 20:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/23\">",
"      Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 1995; 33:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/24\">",
"      Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012; 4:CD003869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/25\">",
"      Hazuka MB, Kinzie JJ. Brain metastases: results and effects of re-irradiation. Int J Radiat Oncol Biol Phys 1988; 15:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/26\">",
"      Wong WW, Schild SE, Sawyer TE, Shaw EG. Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys 1996; 34:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/27\">",
"      Cooper JS, Steinfeld AD, Lerch IA. Cerebral metastases: value of reirradiation in selected patients. Radiology 1990; 174:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36486/abstract/28\">",
"      Son CH, Jimenez R, Niemierko A, et al. Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys 2012; 82:e167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5215 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36486=[""].join("\n");
var outline_f35_40_36486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551955440\">",
"      FAVORABLE VERSUS POOR PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H551955447\">",
"      Recursive partitioning analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H551955454\">",
"      Diagnosis-specific graded prognostic assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H551955603\">",
"      Poor prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WBRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dose and fractionation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Late toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recurrent brain metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Reirradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Surgery or SRS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SYMPTOM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5215\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5215|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/63/8187\" title=\"table 1\">",
"      Brain mets prognosis RTOG RPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/13/18654\" title=\"table 3\">",
"      Graded prognostic assessment for brain metastases by diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/12/19650?source=related_link\">",
"      Patient information: Brain metastases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_40_36487="Indications for nutritional assessment in childhood";
var content_f35_40_36487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for nutritional assessment in childhood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36487/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36487/contributors\">",
"     Sarah M Phillips, MS, RD, LD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36487/contributors\">",
"     Craig Jensen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36487/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36487/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36487/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/40/36487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of nutritional assessment in childhood is to prevent nutritional disorders and the increased morbidity and mortality that accompany them. To meet this goal, pediatric clinicians must know the risk factors for obesity and protein energy malnutrition and must understand the normal and abnormal patterns of growth and the changes in body composition during childhood and adolescence. In addition, they must be able to accurately perform and interpret the results of the nutritional evaluation.",
"   </p>",
"   <p>",
"    Nutritional assessment is the quantitative evaluation of nutritional status. A comprehensive nutritional assessment has five components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dietary, medical, and medication history",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Growth, anthropometric, and body composition measurements",
"     </li>",
"     <li>",
"      Laboratory tests",
"     </li>",
"     <li>",
"      Intervention and monitoring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology of nutritional disorders and the indications for nutritional assessment are reviewed here. The dietary history and the clinical and laboratory features of nutritional disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=see_link\">",
"     \"Dietary history and recommended dietary intake in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32248?source=see_link\">",
"     \"Malnutrition in developing countries: Clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=see_link\">",
"     \"Measurement of growth in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6760?source=see_link\">",
"     \"Measurement of body composition in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22391?source=see_link\">",
"     \"Laboratory and radiologic evaluation of nutritional status in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF NUTRITIONAL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity, acute or chronic protein-energy malnutrition (PEM), and linear growth failure are the most common nutritional disorders in children. In the United States, the prevalence of pediatric obesity has increased more than threefold between 1980 and 2008 (",
"    <a class=\"graphic graphic_figure graphicRef62778 \" href=\"mobipreview.htm?11/30/11758\">",
"     figure 1",
"    </a>",
"    ), and similar trends are seen in many other countries in the developed world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=see_link&amp;anchor=H3#H3\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whereas obesity is commonly identified in otherwise healthy children, PEM and linear growth failure typically occur as a consequence of poor dietary intake, increased nutrient loss, or increased nutrient requirements in children with underlying disorders (",
"    <a class=\"graphic graphic_table graphicRef51044 \" href=\"mobipreview.htm?1/37/1629\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=see_link\">",
"     \"Dietary history and recommended dietary intake in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor intake can be a consequence of disease-induced anorexia, food aversion, dysfunctional parent-child interactions, or the presence of abdominal symptoms such as pain or nausea.",
"     </li>",
"     <li>",
"      Increased gastrointestinal losses can occur secondary to vomiting, diarrhea, malabsorption, or loss of the mucosal integrity of the gastrointestinal tract.",
"     </li>",
"     <li>",
"      Increased urinary nutrient loss is associated with some forms of renal disease and metabolic disorders.",
"     </li>",
"     <li>",
"      Increased nutrient requirements are associated with inflammatory, infectious, or metabolic complications of a variety of disease processes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effects of nutritional disorders on health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional disorders have a variety of health effects. As illustrated by the following studies, protein-energy malnutrition is associated with increased risk of illness and negative impact on the clinical outcome in children with underlying disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32248?source=see_link\">",
"     \"Malnutrition in developing countries: Clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large prospective study, malnourished Sudanese children were more likely to develop febrile illness with diarrhea or cough than were well-nourished children (1.75 to 2.0 times and 1.2 to 1.4 times more likely for diarrhea and cough, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of children undergoing orthotopic liver transplantation demonstrate improved one-month and one-year survival among those who were well-nourished at the time of the transplant compared with those who were undernourished (100 versus 23 percent and 88 versus 38 percent for one-month survival and one-year survival, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, childhood obesity is associated with increased morbidity (eg, hypertension, slipped capital-femoral epiphyses, and impaired immunity) and is an independent risk factor for morbidity and mortality in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In an observational study with more than 50 years of follow up, being overweight in adolescence was a more powerful predictor of adult mortality, cardiovascular disease, colorectal cancer, gout, and arthritis than was being overweight in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NORMAL PATTERNS OF GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of abnormal patterns of growth in children and adolescents cannot be undertaken without an understanding of the normal patterns. The most rapid growth rates in healthy children occur during early infancy and adolescence (",
"    <a class=\"graphic graphic_table graphicRef68720 \" href=\"mobipreview.htm?5/50/5931\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H3#H3\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Normal patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average gain in length during the first year of life is 25 cm. This rate declines abruptly to 11 cm per year during the second and third year of life, then slows again to 6 cm per year in the preschool and school-age child. During the adolescent growth spurt, peak height velocities average 3 and 4 cm per six months in girls and boys, respectively, but may be as high as 5 and 6 cm per six months. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link&amp;anchor=H5#H5\">",
"       \"Normal puberty\", section on 'Peak height velocity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The average gain in weight during the first year of life is 7 kg. This rate declines abruptly during infancy, then averages 2.5 kg per year in the preschool and school-age child. During the adolescent growth spurt, peak weight velocities average 3 kg per six months but may be as high as 6 and 7 kg per six months in girls and boys, respectively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link&amp;anchor=H7#H7\">",
"       \"Normal puberty\", section on 'Weight changes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alterations in height and weight velocity are the earliest predictors of poor nutritional status in children with chronic illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=see_link\">",
"     \"Measurement of growth in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BODY COMPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal patterns of body composition are more difficult to characterize than are normal patterns of growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20721808\">",
"    <span class=\"h2\">",
"     Measurement of body composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body composition can be estimated by calculating body mass index (BMI) (or",
"    <span class=\"nowrap\">",
"     weight/height",
"    </span>",
"    in children younger than two years), which is correlated with fat mass. Fat mass can be measured more directly using techniques such as dual energy x-ray absorptiometry (DXA) or skinfold thickness, but these techniques are generally impractical for clinical use and add little to the clinical evaluation of a patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6760?source=see_link&amp;anchor=H10#H10\">",
"     \"Measurement of body composition in children\", section on 'Measures of body composition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of malnutrition on body composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein-energy malnutrition (PEM) manifests as weight loss in all children. However, the effect of PEM on body composition differs in infants and older children. In the healthy infant, approximately 25 percent of body weight is fat, 15 percent protein, and 60 percent body water (",
"    <a class=\"graphic graphic_table graphicRef70879 \" href=\"mobipreview.htm?9/30/9710\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/11\">",
"     11",
"    </a>",
"    ]. As the infant becomes malnourished, weight loss occurs, the absolute amount of body fat decreases, and the proportion of body fat relative to body weight decreases markedly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the absolute amount of body protein decreases, although the proportion of body protein relative to body weight remains unchanged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32248?source=see_link\">",
"     \"Malnutrition in developing countries: Clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern of weight loss in the older child with chronic disease may differ from that of the child with simple starvation. Children with chronic disease may have substantial weight deficits relative to their age-matched peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the absolute amount of lean body mass generally is reduced to a much greater extent than body fat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR NUTRITIONAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nutritional assessment is warranted if a child meets established screening criteria for increased risk of developing protein-energy malnutrition (PEM), growth failure, or obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20721818\">",
"    <span class=\"h2\">",
"     Growth charts",
"    </span>",
"    &nbsp;&mdash;&nbsp;General screening guidelines for nutritional risk are based upon growth curves that are standardized for the population being measured. As of September 2010, the",
"    <a class=\"external\" href=\"file://www.cdc.gov/growthcharts/\">",
"     Centers for Disease Control (CDC) recommends",
"    </a>",
"    using the following growth curves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/14\">",
"     14",
"    </a>",
"    ]: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=see_link&amp;anchor=H31542395#H31542395\">",
"     \"Measurement of growth in children\", section on 'Recommended growth charts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants and toddlers under two years of age &ndash; use the World Health Organization (WHO) child growth standards [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children two years of age and older &ndash; use the growth reference curves prepared by the CDC in 2000, which are based upon data from five national health examination surveys and five supplementary data sources [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are special growth charts for certain groups of children, which are available through the following links:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Down syndrome",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC1719180/\">",
"       growth charts",
"      </a>",
"     </li>",
"     <li>",
"      Turner syndrome (",
"      <a class=\"graphic graphic_figure graphicRef75558 \" href=\"mobipreview.htm?33/21/34129\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebral palsy (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15962?source=see_link&amp;anchor=H6045874#H6045874\">",
"       \"Management and prognosis of cerebral palsy\", section on 'Evaluation and growth charts'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20722620\">",
"    <span class=\"h2\">",
"     Thresholds for further assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following growth patterns raise concerns for under-nutrition. In general, deficits in weight gain or body mass index (BMI) raise concerns about acute protein-energy malnutrition, while deficits in height or height velocity raise concerns about chronic protein-energy malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight-for-height less than the 15",
"      <sup>",
"       th",
"      </sup>",
"      percentile in a child younger than two years of age",
"     </li>",
"     <li>",
"      BMI less than the 15",
"      <sup>",
"       th",
"      </sup>",
"      percentile in a child older than two years of age",
"     </li>",
"     <li>",
"      BMI that has decreased by two or more major percentile curves on the growth chart (eg, from the 30",
"      <sup>",
"       th",
"      </sup>",
"      to the 7",
"      <sup>",
"       th",
"      </sup>",
"      percentile)",
"     </li>",
"     <li>",
"      Weight gain less than 1 kg every year in a prepubertal child",
"     </li>",
"     <li>",
"      Weight gain less than 1 kg every six months at peak pubertal growth",
"     </li>",
"     <li>",
"      Height-for-age less than the 10",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"     <li>",
"      Height velocity less than 5",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      between two years of age and mid puberty. A clinical evaluation to determine the cause of short stature, which may include a nutritional component, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=see_link\">",
"       \"Diagnostic approach to short stature\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following growth patterns raise concerns for overweight or obesity in children between 2 and 18 years of age: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=see_link\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overweight is defined as a BMI between the 85",
"      <sup>",
"       th",
"      </sup>",
"      and 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age",
"     </li>",
"     <li>",
"      Obesity is defined as a BMI greater than the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age",
"     </li>",
"     <li>",
"      A child whose BMI has increased by two or more major percentile curves is at risk for becoming overweight (eg, from the 40",
"      <sup>",
"       th",
"      </sup>",
"      to the 80",
"      <sup>",
"       th",
"      </sup>",
"      percentile) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A child whose parents are obese also is at risk for developing obesity because of shared genetic and environmental influences. The clinician should monitor the child&rsquo;s growth and provide anticipatory guidance to encourage healthy eating and exercise patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20722611\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above criteria, other children may be at risk for nutritional disorders because of hospitalization, medical conditions (eg, recurrent febrile illness or malignancy), dietary habits, feeding behavior, or activity levels. Nutritional assessment should be performed prospectively in these children to allow early intervention when a high-risk situation is identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hospitalized children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional disorders are particularly common in hospitalized children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of pediatric inpatients of a tertiary-care facility, more than one half had a nutritional disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/18\">",
"       18",
"      </a>",
"      ]. The prevalence of acute and chronic protein-energy malnutrition were 25 and 27 percent, respectively.",
"     </li>",
"     <li>",
"      In another study, 296 children admitted to a medical or surgical ward were studied prospectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/19\">",
"       19",
"      </a>",
"      ]. During the inpatient stay (mean length seven days), weight loss occurred in 65 percent of patients and was greater than 2 percent of admission weight in 45 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute protein-energy malnutrition (PEM) is most likely to occur in infants and toddlers or in adolescents, the age groups most frequently hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/18\">",
"     18",
"    </a>",
"    ]. Chronic malnutrition is more evenly distributed across all age groups. Adolescents are at greatest risk for obesity. Gender or racial and ethnic differences do not influence the prevalence of nutritional disorders in hospitalized children.",
"   </p>",
"   <p>",
"    Children diagnosed with gastrointestinal disease, followed by renal or cardiac disease, are at greatest risk for chronic malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/18\">",
"     18",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    ). Children and adults who are hospitalized for severe burns have unusually high metabolic needs because of the hypermetabolic response to this type of injury. The nutritional assessment and management of these patients is discussed in detail in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4215?source=see_link\">",
"     \"Overview of nutritional support for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The more complex the patient's medical or surgical problem, the greater the likelihood the child is in need of nutritional assessment and intervention. Unfortunately, the complexity of the illness often correlates inversely with the amount of attention given to preventing nutritional depletion or excess early in the patient's course of illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recurrent febrile illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A febrile illness initiates a catabolic response that results in negative body nutrient balance because of the increased urinary loss of body proteins, minerals, and vitamins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/20\">",
"     20",
"    </a>",
"    ]. Negative nutrient balance persists until the febrile illness resolves. However, up to three weeks may be required to replenish the depleted body stores. Failure to pay attention to brief episodes of nutritional depletion can lead to a vicious cycle in which the nutritional status of the child worsens with each repeated illness and makes him or her more vulnerable to subsequent infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of malnutrition among pediatric cancer patients varies widely. Malnutrition is present at diagnosis of cancer in more than 50 percent of children in developing countries. In developed countries, the prevalence of malnutrition ranges from less than 10 percent in children with acute lymphoblastic leukemia to 50 percent in children with advanced neuroblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/21\">",
"     21",
"    </a>",
"    ]. Cancer treatment can contribute to malnutrition in the short term by inducing anorexia, mucositis, emesis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/22\">",
"     22",
"    </a>",
"    ]. Serial measurements of height, weight, and food intake, as well as measurement of serum albumin and prealbumin, should be standard practice in the care of children with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with acute leukemia are at risk for nutritional problems at diagnosis, during treatment, and in long-term follow up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 1019 patients with acute lymphoblastic leukemia (ALL), the prevalence of undernutrition at the time of diagnosis was 7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with ALL typically gain weight excessively during and after two years of therapy and appear to have an increased risk of becoming obese [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. The mechanisms for this association have not been established but may include reduced habitual physical activity and associated reduced total energy expenditure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/28\">",
"       28",
"      </a>",
"      ] and possibly subtle hypothalamic-pituitary dysfunction induced by cranial radiation therapy (CRT). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Obesity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cancer treatment can have long-term effects on growth through a variety of mechanisms, including disruption of hypothalamic-pituitary function causing growth hormone deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Developmental disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with motor and cognitive dysfunction are predisposed to feeding disorders. In one study, nutrition evaluation was performed in 79 children with moderate to severe motor or cognitive dysfunction who were referred for diagnosis and treatment of feeding or nutritional problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/29\">",
"     29",
"    </a>",
"    ]. The primary diagnoses included cerebral palsy with mental retardation, prematurity, chromosomal abnormality, central nervous system (CNS) malformation, congenital infection, pervasive developmental delay, perinatal asphyxia, and fetal alcohol syndrome. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Energy intake at the time of entry into the study, determined by dietary recall and three-day food records, was approximately 80 percent of the recommended daily allowance (RDA).",
"     </li>",
"     <li>",
"      Gastroesophageal reflux (GER) with or without aspiration was present in 44 of 79 patients, oropharyngeal dysphagia in 21, and aversive feeding behaviors in 14.",
"     </li>",
"     <li>",
"      After approximately two years of therapy based upon diagnosis (eg, medical treatment of GER, feeding therapy, gastrostomy tube placement), energy intake increased to 123 percent of the RDA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The assessment and management of nutritional problems in children with cerebral palsy are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15962?source=see_link&amp;anchor=H24#H24\">",
"     \"Management and prognosis of cerebral palsy\", section on 'Feeding disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paradoxically, there is also a high prevalence of obesity among some populations of children and adults with intellectual disability, particularly those with less severe disabilities and certain specific disorders such as Down syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The rates of obesity also vary depending on the country and the clinical setting in which the affected individual lives. In the United States, individuals living in smaller settings (families and group homes) have higher rates of obesity than those living in larger institutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/31\">",
"     31",
"    </a>",
"    ]. Nutritional management of individuals with Down syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13224?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of Down syndrome\", section on 'Obesity prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional children at risk for nutritional disorders are those who are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36487/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Taking medications",
"     </li>",
"     <li>",
"      Anemic",
"     </li>",
"     <li>",
"      Allergic or intolerant to certain foods",
"     </li>",
"     <li>",
"      On a special diet or formula (prescribed or self-imposed)",
"     </li>",
"     <li>",
"      Receiving alternative or complementary therapies that include dietary modification (eg, a gluten-free diet), if done without guidance to ensure a balanced diet",
"     </li>",
"     <li>",
"      Using supplemental foods or vitamins",
"     </li>",
"     <li>",
"      Difficult to feed or have dental problems",
"     </li>",
"     <li>",
"      Not ambulatory",
"     </li>",
"     <li>",
"      Sedentary or overly active",
"     </li>",
"     <li>",
"      Tube fed (via gastrostomy, jejunostomy or nasogastric tube)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24056931\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both under-nutrition and over-nutrition have short- and long-term effects on growth, morbidity, and mortality. Identifying children with or at risk for nutritional problems is an important part of preventive medical care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serial measurements of weight and height are a valuable screen for nutritional problems when compared with expected growth rates for healthy children. The most rapid growth rates in healthy children occur during early infancy and adolescence (",
"      <a class=\"graphic graphic_table graphicRef68720 \" href=\"mobipreview.htm?5/50/5931\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Normal patterns of growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Protein-energy malnutrition (PEM) manifests as weight loss in all children. However, the effect of PEM on body composition differs in infants and older children. As the infant becomes malnourished, weight loss occurs, the absolute amount of body fat decreases, and the proportion of body fat relative to body weight decreases markedly. In the older child with chronic disease, the absolute amount of lean body mass generally is reduced to a much greater extent than body fat. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of malnutrition on body composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following growth patterns raise concerns for under-nutrition. In general, deficits in weight gain or body mass index (BMI) raise concerns about acute PEM while deficits in height or height velocity raise concerns about chronic PEM. (See",
"      <a class=\"local\" href=\"#H20722620\">",
"       'Thresholds for further assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Weight-for-height less than the 15",
"      <sup>",
"       th",
"      </sup>",
"      percentile in a child younger than two years of age",
"     </li>",
"     <li>",
"      BMI less than the 15",
"      <sup>",
"       th",
"      </sup>",
"      percentile in a child older than two years of age",
"     </li>",
"     <li>",
"      BMI that has decreased by two or more major percentile curves on the growth chart (eg, from the 30",
"      <sup>",
"       th",
"      </sup>",
"      to the 7",
"      <sup>",
"       th",
"      </sup>",
"      percentile)",
"     </li>",
"     <li>",
"      Weight gain less than 1 kg every year in a prepubertal child",
"     </li>",
"     <li>",
"      Weight gain less than 1 kg every six months at peak pubertal growth",
"     </li>",
"     <li>",
"      Height-for-age less than the 10",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"     <li>",
"      Height velocity less than 5",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      between two years of age and mid puberty",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nutritional assessment also is indicated for children who are overweight or obese, for those whose BMI percentile is increasing rapidly, and for those with parents who are obese. The clinician should monitor the child&rsquo;s growth and provide anticipatory guidance to encourage healthy eating and exercise patterns. (See",
"      <a class=\"local\" href=\"#H20722620\">",
"       'Thresholds for further assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the anthropometric parameters outlined above, nutritional assessment is indicated in many hospitalized children (particularly infants and toddlers, and those with severe burn injuries or chronic illnesses), and in children with recurrent febrile illness or cancers. Children with developmental disabilities including cerebral palsy are at risk for malnutrition and obesity, depending on the degree and type of disability, and the setting in which they live. (See",
"      <a class=\"local\" href=\"#H20722611\">",
"       'Special populations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/1\">",
"      Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/2\">",
"      Kossmann J, Nestel P, Herrera MG, et al. Undernutrition in relation to childhood infections: a prospective study in the Sudan. Eur J Clin Nutr 2000; 54:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/3\">",
"      Shepherd RW, Chin SE, Cleghorn GJ, et al. Malnutrition in children with chronic liver disease accepted for liver transplantation: clinical profile and effect on outcome. J Paediatr Child Health 1991; 27:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/4\">",
"      Ishikawa M, Lynch SV, Balderson GA, et al. Liver transplantation in Japanese and Australian/New Zealand children with biliary atresia: a 10-year comparative study. Eur J Surg 1999; 165:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/5\">",
"      Must A, Jacques PF, Dallal GE, et al. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992; 327:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/6\">",
"      van Dam RM, Willett WC, Manson JE, Hu FB. The relationship between overweight in adolescence and premature death in women. Ann Intern Med 2006; 145:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/7\">",
"      Must A, Phillips SM, Naumova EN. Occurrence and timing of childhood overweight and mortality: findings from the Third Harvard Growth Study. J Pediatr 2012; 160:743.",
"     </a>",
"    </li>",
"    <li>",
"     Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Advance data from vital and health statistics. Number 314. National Center for Health Statistics; Centers for Disease Control and Prevention, Hyattsville, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/9\">",
"      Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/10\">",
"      Wells JC, Fuller NJ, Dewit O, et al. Four-component model of body composition in children: density and hydration of fat-free mass and comparison with simpler models. Am J Clin Nutr 1999; 69:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/11\">",
"      Butte N, Heinz C, Hopkinson J, et al. Fat mass in infants and toddlers: comparability of total body water, total body potassium, total body electrical conductivity, and dual-energy X-ray absorptiometry. J Pediatr Gastroenterol Nutr 1999; 29:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/12\">",
"      Fjeld CR, Schoeller DA, Brown KH. Body composition of children recovering from severe protein-energy malnutrition at two rates of catch-up growth. Am J Clin Nutr 1989; 50:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/13\">",
"      Shepherd RW, Holt TL, Johnson LP, et al. Leucine metabolism and body cell mass in cystic fibrosis. Nutrition 1995; 11:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/14\">",
"      Grummer-Strawn LM, Reinold C, Krebs NF, Centers for Disease Control and Prevention (CDC). Use of World Health Organization and CDC growth charts for children aged 0-59 months in the United States. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The WHO Child Growth Standards. Available at: www.who.int/childgrowth/standards/en/ (Accessed on February 27, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/16\">",
"      Mei Z, Grummer-Strawn LM, Pietrobelli A, et al. Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. Am J Clin Nutr 2002; 75:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/17\">",
"      Taveras EM, Rifas-Shiman SL, Sherry B, et al. Crossing growth percentiles in infancy and risk of obesity in childhood. Arch Pediatr Adolesc Med 2011; 165:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/18\">",
"      Hendricks KM, Duggan C, Gallagher L, et al. Malnutrition in hospitalized pediatric patients. Current prevalence. Arch Pediatr Adolesc Med 1995; 149:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/19\">",
"      Sermet-Gaudelus I, Poisson-Salomon AS, Colomb V, et al. Simple pediatric nutritional risk score to identify children at risk of malnutrition. Am J Clin Nutr 2000; 72:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/20\">",
"      Beisel WR. Interrelated changes in host metabolism during generalized infectious illness. Am J Clin Nutr 1972; 25:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/21\">",
"      Sala A, Pencharz P, Barr RD. Children, cancer, and nutrition--A dynamic triangle in review. Cancer 2004; 100:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/22\">",
"      Barr RD. Nutrition, cancer, and children. Nutrition 2002; 18:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/23\">",
"      Ruiz-Arg&uuml;elles GJ. Consensus statement: nutritional morbidity in children with cancer. Haematologica 1999; 84:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/24\">",
"      Elhasid R, Laor A, Lischinsky S, et al. Nutritional status of children with solid tumors. Cancer 1999; 86:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/25\">",
"      Reilly JJ, Weir J, McColl JH, Gibson BE. Prevalence of protein-energy malnutrition at diagnosis in children with acute lymphoblastic leukemia. J Pediatr Gastroenterol Nutr 1999; 29:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/26\">",
"      Veringa SJ, van Dulmen-den Broeder E, Kaspers GJ, Veening MA. Blood pressure and body composition in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/27\">",
"      Garmey EG, Liu Q, Sklar CA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2008; 26:4639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/28\">",
"      Ventham JC, Reilly JJ. Childhood leukaemia: a model of pre-obesity. Proc Nutr Soc 1999; 58:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/29\">",
"      Schwarz SM, Corredor J, Fisher-Medina J, et al. Diagnosis and treatment of feeding disorders in children with developmental disabilities. Pediatrics 2001; 108:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/30\">",
"      Stewart L, Van de Ven L, Katsarou V, et al. High prevalence of obesity in ambulatory children and adolescents with intellectual disability. J Intellect Disabil Res 2009; 53:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/31\">",
"      Rimmer JH, Yamaki K. Obesity and intellectual disability. Ment Retard Dev Disabil Res Rev 2006; 12:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/32\">",
"      Rimmer JH, Wang E. Obesity prevalence among a group of Chicago residents with disabilities. Arch Phys Med Rehabil 2005; 86:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36487/abstract/33\">",
"      Baer MT, Harris AB. Pediatric nutrition assessment: identifying children at risk. J Am Diet Assoc 1997; 97:S107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5358 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36487=[""].join("\n");
var outline_f35_40_36487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24056931\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY OF NUTRITIONAL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effects of nutritional disorders on health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NORMAL PATTERNS OF GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BODY COMPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20721808\">",
"      Measurement of body composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of malnutrition on body composition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR NUTRITIONAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20721818\">",
"      Growth charts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20722620\">",
"      Thresholds for further assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20722611\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hospitalized children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recurrent febrile illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Developmental disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24056931\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5358|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/30/11758\" title=\"figure 1\">",
"      US trends in childhood obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/21/34129\" title=\"figure 2\">",
"      Turner syndrome growth chart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/37/1629\" title=\"table 1\">",
"      Nutrition risk chronic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/50/5931\" title=\"table 2\">",
"      Normal growth rates children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/30/9710\" title=\"table 3\">",
"      Body composition of healthy children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=related_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22391?source=related_link\">",
"      Laboratory and radiologic evaluation of nutritional status in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15962?source=related_link\">",
"      Management and prognosis of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13224?source=related_link\">",
"      Management of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6760?source=related_link\">",
"      Measurement of body composition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_40_36488="Treatment of herpes simplex virus type 1 infection in immunocompetent patients";
var content_f35_40_36488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36488/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36488/contributors\">",
"     Robyn S Klein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36488/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36488/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36488/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36488/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/40/36488/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1) may cause vesicular lesions of the lips and oral mucosa. HSV-1 can also lead to clinical disease in a wide variety of other anatomic locations, including the genitalia, liver, lung, eye, and central nervous system.",
"   </p>",
"   <p>",
"    The treatment of primary and recurrent HSV-1 infections in the immunocompetent host will be reviewed here. The epidemiology, clinical manifestations, diagnosis and prevention of this infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=see_link\">",
"     \"Epidemiology of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39669?source=see_link\">",
"     \"Prevention of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prophylaxis of HSV-1 infections in the immunocompromised patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal clinical manifestation of primary HSV-1 infection is gingivostomatitis, sometimes associated with pharyngitis.",
"   </p>",
"   <p>",
"    Reactivation of prior HSV-1 infection occurs in the trigeminal sensory ganglion. Reactivation may lead to cutaneous, and more commonly, mucocutaneous disease, known as herpes labialis, which occurs along the vermillion border of the lip. In general, symptomatic primary HSV infections (ie, initial HSV infection in a seronegative host) are associated with an increased risk of constitutional symptoms, a longer duration of lesions, and prolonged viral shedding compared with recurrent disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of HSV-1 infection in the immunocompetent host depends upon a variety of considerations including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whether the patient has primary HSV-1 infection or reactivation disease",
"     </li>",
"     <li>",
"      The severity of symptoms",
"     </li>",
"     <li>",
"      The site of infection (eg, oropharynx versus central nervous system)",
"     </li>",
"     <li>",
"      The frequency of recrudescence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral agents for HSV infection include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ; metabolites of these nucleoside derivatives interfere with the synthesis of viral DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/1\">",
"     1",
"    </a>",
"    ]. Of all the human herpesviruses, acyclovir has the greatest in vitro activity against HSV-1 and HSV-2.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    have greater oral bioavailability than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/2\">",
"     2",
"    </a>",
"    ] and are dosed less frequently, but are generally more expensive. The margin of safety of all three medications is excellent since these medications are selectively converted to active compounds within virally infected cells. Acyclovir is the only medication of this group that can be dosed intravenously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=see_link\">",
"     \"Valacyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=see_link\">",
"     \"Famciclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and the related compound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    are also available, and have been studied for recurrent herpes labialis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment with these formulations requires frequent daily applications (eg, acyclovir five times a day or penciclovir nine times a day). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Recurrent infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRIMARY INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gingivostomatitis and pharyngitis are most commonly seen in young children (eg, one to six years of age), although severe primary HSV infection can sometimes be observed in older children, adolescents, and young adults. Although gingivostomatitis and pharyngitis are generally self-limiting illnesses, severe infection can lead to dehydration because of severe odynophagia.",
"   </p>",
"   <p>",
"    The management of older children (greater than 12 years of age), adolescents, and young adults is discussed below. Special issues related to the management of younger children &lt;12 years of age is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=see_link&amp;anchor=H11#H11\">",
"     \"Herpetic gingivostomatitis in young children\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antiviral treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small treatment trials of antiviral therapy suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is beneficial if begun early during primary HSV infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Most of the available data on the efficacy of antiviral treatment of primary HSV infections is in young children, as discussed below.",
"   </p>",
"   <p>",
"    In a randomized, double-blind trial, 72 children (one to six years of age) with herpes gingivostomatitis were treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for one week (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a dose of 200 mg five times daily) within three days after the onset of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/3\">",
"     3",
"    </a>",
"    ]. Acyclovir was well tolerated without any significant side effects. Compared with placebo, patients who were assigned to the treatment arm had [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Earlier disappearance of fever (one versus three days)",
"     </li>",
"     <li>",
"      A shorter duration of lesions (median four versus ten days)",
"     </li>",
"     <li>",
"      Decreased duration of odynophagia (four versus seven days)",
"     </li>",
"     <li>",
"      Reduced viral shedding (one versus five days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    does not diminish the risk of HSV-1 recurrences over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized clinical trial data evaluating other related antiviral agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , for the treatment of primary HSV pharyngitis or gingivostomatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Timing of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt initiation of therapy within 72 hours is important to obtain maximal clinical benefit. However, if a patient presents after this time frame with ongoing development of new lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    significant pain, antiviral therapy should still be offered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who present with gingivostomatitis often require either topical or oral administration of analgesics. Intravenous rehydration may be required for patients with severe odynophagia.",
"   </p>",
"   <p>",
"    Painful oral and labial lesions of primary HSV-1 infection can be treated with viscous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , zilactin, or ziladent. Short-term pain relief (10 to 15 minutes) can be achieved via mouth rinses with viscous lidocaine. Zilactin, a nonprescription topical medication containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29714?source=see_link\">",
"     hydroxypropyl cellulose",
"    </a>",
"    , adheres to mucosa and may be used to protect lesions from irritants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/6\">",
"     6",
"    </a>",
"    ]. Ziladent, a similar agent with the addition of the topical anesthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    , can provide pain relief for up to six hours. In severe cases, oral opiates, usually in the form of elixirs, may be required for adequate pain relief. Adolescents and adults may also benefit from topical analgesics but rarely require oral pain medications. In addition, antiseptics may hasten drying of lesions and decrease the risk of bacterial superinfection in both children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Suggestions for clinical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trial data demonstrate that compared with untreated disease, oral antiviral therapy significantly decreases the duration and severity of gingivostomatitis in children with minimal adverse drug effects. No placebo-controlled trial data are available in older children or adults.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    can be administered orally at 200 mg five times daily. However, for greater patient convenience and adherence, we often treat patients with daily dosing of acyclovir at 400 mg every eight hours. This approach is based on the pharmacokinetics of the drug and treatment guideline recommendations for genital HSV infections, which have been extrapolated to the treatment of oral HSV infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/8\">",
"     8",
"    </a>",
"    ]. Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , which has demonstrated equivalence to acyclovir in the treatment of genital herpes, affords twice-daily dosing, but is generally more expensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/9\">",
"     9",
"    </a>",
"    ]. In summary, treatment options for adolescents and adults include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      : 400 mg PO three times per day or 200 mg PO five times per day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      : 500 mg three times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      : 1000 mg PO twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The usual duration of treatment is 7 to 10 days depending on the severity of symptoms and response to therapy. Patients with severe odynophagia may sometimes require hospitalization for intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy (5",
"    <span class=\"nowrap\">",
"     mg/kg/dose",
"    </span>",
"    every eight hours) and intravenous fluids. Symptomatic pain relief and use of astringents may be other components of patient management for severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECURRENT INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent herpes labialis is generally associated with less severe clinical symptoms and a shorter duration of illness than primary disease. Some patients recognize that reactivation of disease is about to occur due to the onset of prodromal symptoms (eg, a sensation of pain, tingling, burning), which precede the development of vesicles.",
"   </p>",
"   <p>",
"    A small subset of patients have serious systemic complications associated with HSV-1 recurrences such as erythema multiforme, eczema herpeticum or recurrent aseptic meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various strategies may be employed in the management of the patient with HSV-1 reactivation disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Episodic therapy",
"     </li>",
"     <li>",
"      Chronic suppressive therapy",
"     </li>",
"     <li>",
"      No treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision of whether or not to treat recurrent herpes labialis should be evaluated individually; the clinical decision will need to weigh the severity of symptoms, the frequency of recurrences, as well as patient preference and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a well-identified inciting event may be excellent candidates for a prophylactic approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39669?source=see_link\">",
"     \"Prevention of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     No treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients experience occasional clinical recurrences with minimal symptoms; no antiviral therapy is necessary for these patients. Other options include symptomatic relief with local anesthetics and antiseptics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Episodic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have evaluated both topical and oral antiviral therapy for sporadic recurrences of HSV-1 infection. &nbsp;Because of the rapid development of vesicles once prodromal symptoms occur, and the rapid decline in viral shedding during reactivation disease (&lt;48 hours), episodic treatment must be initiated quickly to be effective; even then the clinical benefit is modest. Patients with prodromal symptoms may be good candidates for episodic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Topical antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of patients with sporadic recurrences of HSV-1 infection showed that antiviral therapy with topical creams or ointments are, at best, of modest benefit. Many of these topical applications are based on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or related compounds (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    ) as the active component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest randomized trials assigned 1573 patients with frequent recurrences of HSV-1 infection to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    cream or placebo every two hours during the day for four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/12\">",
"     12",
"    </a>",
"    ]. The penciclovir cream decreased the time to lesion healing (4.8 versus 5.5 days) and the duration of pain (3.5 versus 4.1 days); viral shedding was also reduced.",
"   </p>",
"   <p>",
"    Some studies of topical agents unrelated to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    that are available over the counter in the United States (eg, benzalkonium chloride [Viroxyn],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/57/6034?source=see_link\">",
"     docosanol",
"    </a>",
"    [Abreva]) have suggested benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], whereas others have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    , which is approved for topical treatment of genital warts, was evaluated in 47 subjects with recurrent herpes labialis episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/17\">",
"     17",
"    </a>",
"    ]. Application of imiquimod led to severe local inflammation in several subjects leading to early discontinuation of study enrollment; thus, imiquimod is not recommended for herpes labialis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Oral antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the need for frequent application of creams and the modest clinical benefit of topical therapy, clinical trials have assessed the efficacy of oral antiviral therapy for the treatment of HSV-1 infections. In general, placebo-controlled trials have demonstrated that antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    hastens the healing of lesions if treatment is initiated during the prodromal stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/18\">",
"     18",
"    </a>",
"    ]. There are no clinical trials directly comparing any of these antiviral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies illustrate the range of results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 174 immunocompetent subjects were randomly assigned to oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg taken five times daily for five days) versus placebo within one hour of onset of prodromal symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/20\">",
"       20",
"      </a>",
"      ]. The acyclovir group had a decreased frequency of HSV culture-positive lesions (25 versus 48 percent). Treatment decreased the duration of the lesions that did occur by approximately 2.1 days compared with placebo.",
"     </li>",
"     <li>",
"      In a randomized, double-blind trial, 701 patients with recurrent herpes labialis were randomly assigned to placebo or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      (as a single dose of 1500 mg or 750 mg twice a day for a single day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/21\">",
"       21",
"      </a>",
"      ]. All were instructed to take their assigned treatment within one hour of onset of prodromal symptoms. The time to healing of lesions was significantly shorter in the two treatment groups (4.4 and 4.0 days) compared with placebo (6.2 days).",
"     </li>",
"     <li>",
"      Two randomized trials compared short-course regimens of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      administered for prodromal symptoms for one day (2 g twice daily) or two days (2 g twice on the first day and 1 g twice on the second day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Valacyclovir shortened outbreaks by approximately one day compared with placebo; treatment for one day was as effective as treatment for two days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these results, we suggest rapid initiation of antiviral therapy for patients with episodic HSV-1 and a well-defined prodrome. The choice of agents includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      (200 or 400 mg five times daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      (750 mg twice daily for one day or 1500 mg as a single dose)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      (2 g twice daily for one day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Single-day dosing with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    affords greater patient convenience and overall lower cost compared with five days of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chronic suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic suppression with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    helps to reduce the number of clinical HSV episodes in individuals with frequently recurrent lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The safety of a daily suppressive regimen has also been demonstrated among patients using acyclovir continuously for up to one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/24\">",
"     24",
"    </a>",
"    ]. There are no studies directly comparing acyclovir and valacyclovir; there are no data on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    for this indication.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled trial, 56 adults with a history of frequently recurrent herpes labialis (six or more",
"      <span class=\"nowrap\">",
"       episodes/year)",
"      </span>",
"      were observed during a four-month period; 22 patients who had two or more episodes of herpes labialis were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg twice daily) or matched placebo. After the first treatment period, patients were switched to the alternate arm for another four months. Recurrent outbreaks were determined by physical examination and by viral culture. The acyclovir group had a lower mean number of recurrences (0.85 versus 1.8 recurrences) and a longer median time to their first documented recurrence (118 versus 46 days).",
"     </li>",
"     <li>",
"      Two small randomized, double-blind trials evaluated oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (500 mg once daily) versus placebo for 16 weeks in patients with frequent recurrences (four or more episodes during the previous year) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/26\">",
"       26",
"      </a>",
"      ]. Patients receiving valacyclovir were more likely to remain free of recurrences during the four-month period than those receiving placebo (60 versus 38 percent). The time to the first recurrence was significantly longer with antiviral therapy (13 versus 9.6 weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic suppressive therapy for virologically confirmed recurrent HSV in immunocompetent patients is indicated when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrences are frequent or bothersome to the patient (eg, associated with significant disfiguring lesions, pain)",
"     </li>",
"     <li>",
"      Recurrences are associated with serious systemic complications (eg, erythema multiforme, eczema herpeticum or recurrent aseptic meningitis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/7,27\">",
"       7,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not have a specific prodrome are particularly good candidates for suppressive therapy. The patient should be counseled that chronic suppression does not change the natural history of HSV infection (ie, the number of recurrences) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/28\">",
"     28",
"    </a>",
"    ]. The decision to use chronic suppressive therapy should also include cost considerations, which are significantly greater than with episodic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prophylaxis for recurrent HSV with specific trigger",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both iatrogenic (facial surgery) and natural triggers (excessive sunlight) can lead to predictable HSV-1 infections in some patients. The management of such recurrences of HSV-1 is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39669?source=see_link\">",
"     \"Prevention of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER HSV-1 INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary and recurrent HSV-1 infections occur at a variety of other anatomic sites, although with less frequency than herpes gingivostomatitis and labialis. Involvement of the skin, eye, central nervous system, or genitals can occur; rarely, disseminated disease involving visceral organs, such as the liver and spleen, can be seen in an immunocompetent host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 cutaneous skin lesions may occur in a patient with primary HSV infection. The etiology of these skins infections is thought to be due to autoinoculation from mucocutaneous lesions or through primary inoculation of the skin during viremia (which is prolonged in primary infection compared with reactivation).",
"   </p>",
"   <p>",
"    Although there are no formal treatment studies of the treatment of primary skin infections due to HSV-1 infection, our approach is the same as that for first episode gingivostomatitis or pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/30\">",
"     30",
"    </a>",
"    ]. We use either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg TID) or other related nucleoside analogues (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ) for 7 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV-1 can cause multiple cutaneous skin lesions among athletes in contact sports, referred to as herpes gladiatorum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/31\">",
"     31",
"    </a>",
"    ]. Athletes should not participate in contact sports until all herpes lesions have encrusted. Antiviral therapy can expedite healing of lesions during primary and recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, primary HSV-1 infection may lead to widespread vesicular eruptions in the immunocompetent host; this type of extensive cutaneous involvement is sometimes seen in association with disseminated disease involving the liver, lungs, and central nervous system (ie, aseptic meningitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/33\">",
"     33",
"    </a>",
"    ]. Disseminated disease should be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times daily); the optimal duration of treatment is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Atopic eczema, burns, and other skin disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ectopic eczema or burns are at risk of severe orofacial HSV infections (\"eczema herpeticum\") due to reactivation disease, which may progress rapidly to involve extensive areas of skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/34\">",
"     34",
"    </a>",
"    ]. In a retrospective cohort study performed at a single major burn center, 14 of 95 patients with significant orofacial burns who underwent intubation developed cutaneous vesicular rash and fever secondary to HSV-1 reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/35\">",
"     35",
"    </a>",
"    ]. We do not routinely prophylactically treat burn patients for HSV-1. However, early recognition and treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burn patients with vesicular lesions should be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    administered at doses also adequate to treat varicella-zoster virus (ie, 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times daily) until cultures confirm cutaneous HSV-1 infection; then dosing can be reduced to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outpatients with severe dermatologic conditions who have primary HSV-1 infection or reactivation disease should be treated with oral antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or a related agent to limit the extent of cutaneous involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis is a rare manifestation of HSV-1 infection in immunocompetent hosts, which is associated with high mortality. In one series, antiviral agents were used in nine patients with HSV hepatitis; only four patients survived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/36\">",
"     36",
"    </a>",
"    ]. Nevertheless, high-dose parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is recommended for suspected or biopsy-proven cases. On biopsy, viral inclusions (eg, Cowdry bodies) may be seen. Rash is not always present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ocular infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV keratitis (corneal infection and inflammation) is a major cause of blindness from corneal scarring and opacity worldwide. The treatment of herpes simplex virus keratitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=see_link\">",
"     \"Herpes simplex keratitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV is the most common cause of acute, nonepidemic viral encephalitis in the United States. HSV has also been implicated as an etiologic agent of Bell's palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/37\">",
"     37",
"    </a>",
"    ]. The treatment of these clinical entities is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=see_link\">",
"     \"Bell's palsy: Prognosis and treatment in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Genital ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 can also cause primary and recurrent genital ulcers. The treatment of this entity is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     FUTURE DRUG DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidate antiviral agents are also in development, which inhibit the helicase-primase enzyme of HSV-1 and -2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Two of these agents, BILS 179 BS and BAY 57-1293, are effective in clearing both HSV-1 and -2 in murine models of infection following oral administration; BILS 179 BS appears to be active even if administered as late as 65 hours after infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/38\">",
"     38",
"    </a>",
"    ] and BAY 57-1293 may decrease the frequency and severity of recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36488/abstract/39\">",
"     39",
"    </a>",
"    ]. Both drugs are currently in clinical trials in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/24/4482?source=see_link\">",
"       \"Patient information: Cold sores (oral herpes) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The principal manifestation of primary HSV-1 infection is gingivostomatitis with or without pharyngitis. Reactivation of HSV-1 occurs in the trigeminal sensory ganglion and may lead to mucocutaneous disease, known as herpes labialis, which occurs along the vermillion border of the lip. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral agents for HSV infection include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      ; metabolites of these nucleoside derivatives interfere with the synthesis of viral DNA and are all well tolerated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Available agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although gingivostomatitis and pharyngitis are self-limiting illnesses, severe infection can lead to significant oral pain and dehydration. Early antiviral therapy within 72 hours of symptom onset leads to earlier healing of lesions, decreased pain, and a shorter duration of fever. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Primary infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with gingivostomatitis or pharyngitis due to primary HSV infection, we recommend oral antiviral therapy rather than no antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      (400 mg three times daily for 7 to 10 days) is a suitable option for both older children and adults. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Primary infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent herpes labialis is generally associated with less severe clinical symptoms and a shorter duration of illness than primary disease. Some patients recognize that reactivation of disease is about to occur due to the onset of prodromal symptoms (eg, a sensation of pain, tingling, burning), which precede the development of vesicles.",
"     </li>",
"     <li>",
"      Various strategies may be employed in the management of the patient with HSV-1 reactivation disease including episodic therapy, chronic suppressive therapy, or no treatment at all. The vast majority of patients do not require treatment for mild self-limited disease.",
"     </li>",
"     <li>",
"      Antiviral therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      shortens the duration and severity of symptoms and hastens healing of lesions if initiated during the prodromal stage. For patients with recurrent symptomatic herpes labialis and an identifiable prodrome, we suggest episodic oral antiviral therapy rather than no therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Single-day dosing of famciclovir (1500 mg single dose) or valacyclovir (2 g twice daily for one day) is efficacious, convenient, safe, and cost effective.",
"     </li>",
"     <li>",
"      Chronic suppressive therapy decreases the number of recurrences of herpes labialis among patients with frequent recurrences of HSV (more than four",
"      <span class=\"nowrap\">",
"       episodes/year).",
"      </span>",
"      For patients with multiple painful or disfiguring lesions who do not have an identifiable prodrome, we suggest chronic suppressive therapy rather than no antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We also suggest chronic suppressive therapy for patients who have HSV recurrences associated with serious complications, such as recurrent aseptic meningitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/1\">",
"      Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/2\">",
"      Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002; 186 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/3\">",
"      Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 1997; 314:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/4\">",
"      Ducoulombier H, Cousin J, Dewilde A, et al. [Herpetic stomatitis-gingivitis in children: controlled trial of acyclovir versus placebo]. Ann Pediatr (Paris) 1988; 35:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/5\">",
"      O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989; 37:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/6\">",
"      Rodu B, Mattingly G. Oral mucosal ulcers: diagnosis and management. J Am Dent Assoc 1992; 123:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/7\">",
"      Vestey JP, Norval M. Mucocutaneous infections with herpes simplex virus and their management. Clin Exp Dermatol 1992; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/8\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/9\">",
"      Chauvin PJ, Ajar AH. Acute herpetic gingivostomatitis in adults: a review of 13 cases, including diagnosis and management. J Can Dent Assoc 2002; 68:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/10\">",
"      Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008; 168:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/11\">",
"      Gilbert SC. Management and prevention of recurrent herpes labialis in immunocompetent patients. Herpes 2007; 14:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/12\">",
"      Spruance SL, Rea TL, Thoming C, et al. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997; 277:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/13\">",
"      Spruance SL, Nett R, Marbury T, et al. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002; 46:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/14\">",
"      Sacks SL, Thisted RA, Jones TM, et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol 2001; 45:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/15\">",
"      McCarthy JP, Browning WD, Teerlink C, Veit G. Treatment of herpes labialis: comparison of two OTC drugs and untreated controls. J Esthet Restor Dent 2012; 24:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/16\">",
"      McKeough MB, Spruance SL. Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch Dermatol 2001; 137:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/17\">",
"      Bernstein DI, Spruance SL, Arora SS, et al. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis 2005; 41:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/18\">",
"      Arduino PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis 2006; 12:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/19\">",
"      Jensen LA, Hoehns JD, Squires CL. Oral antivirals for the acute treatment of recurrent herpes labialis. Ann Pharmacother 2004; 38:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/20\">",
"      Spruance SL, Stewart JC, Rowe NH, et al. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990; 161:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/21\">",
"      Spruance SL, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006; 55:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/22\">",
"      Spruance SL, Jones TM, Blatter MM, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003; 47:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/23\">",
"      Valacyclovir (valtrex) for herpes labialis. Med Lett Drugs Ther 2002; 44:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/24\">",
"      Worrall G. Acyclovir in recurrent herpes labialis. BMJ 1996; 312:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/25\">",
"      Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993; 118:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/26\">",
"      Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis 2003; 71:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/27\">",
"      Green JA, Spruance SL, Wenerstrom G, Piepkorn MW. Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir. Ann Intern Med 1985; 102:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/28\">",
"      Nikkels AF, Pi&egrave;rard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol 2002; 3:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/29\">",
"      Arduino PG, Porter SR. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med 2008; 37:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/30\">",
"      Kesson AM. Use of aciclovir in herpes simplex virus infections. J Paediatr Child Health 1998; 34:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/31\">",
"      Meulener M, Smith BL. Herpes gladiatorum with ocular involvement in a mixed martial arts fighter. Cutis 2011; 87:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/32\">",
"      Usatine RP, Tinitigan R. Nongenital herpes simplex virus. Am Fam Physician 2010; 82:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/33\">",
"      Moedy JL, Lerman SJ, White RJ. Fatal disseminated herpes simplex virus infection in a healthy child. Am J Dis Child 1981; 135:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/34\">",
"      Foley FD, Greenawald KA, Nash G, Pruitt BA Jr. Herpesvirus infection in burned patients. N Engl J Med 1970; 282:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/35\">",
"      Fidler PE, Mackool BT, Schoenfeld DA, et al. Incidence, outcome, and long-term consequences of herpes simplex virus type 1 reactivation presenting as a facial rash in intubated adult burn patients treated with acyclovir. J Trauma 2002; 53:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/36\">",
"      Mantry P, Desai D, Kumar V, Udwadia T. Herpes simplex hepatitis. Indian J Gastroenterol 1997; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/37\">",
"      Furuta Y, Fukuda S, Chida E, et al. Reactivation of herpes simplex virus type 1 in patients with Bell's palsy. J Med Virol 1998; 54:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/38\">",
"      Crute JJ, Grygon CA, Hargrave KD, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002; 8:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36488/abstract/39\">",
"      Kleymann G, Fischer R, Betz UA, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002; 8:392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8345 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36488=[""].join("\n");
var outline_f35_40_36488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRIMARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age of onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antiviral treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Timing of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Suggestions for clinical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECURRENT INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - No treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Episodic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Topical antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Oral antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chronic suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prophylaxis for recurrent HSV with specific trigger",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER HSV-1 INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Atopic eczema, burns, and other skin disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ocular infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      FUTURE DRUG DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=related_link\">",
"      Bell's palsy: Prognosis and treatment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=related_link\">",
"      Epidemiology of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=related_link\">",
"      Famciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=related_link\">",
"      Herpetic gingivostomatitis in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/24/4482?source=related_link\">",
"      Patient information: Cold sores (oral herpes) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39669?source=related_link\">",
"      Prevention of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=related_link\">",
"      Valacyclovir: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_40_36489="Open cholecystectomy";
var content_f35_40_36489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Open cholecystectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36489/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36489/contributors\">",
"     Daniel T Dempsey, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36489/contributors\">",
"     Shefali Agrawal, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36489/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/40/36489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/40/36489/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/40/36489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1162120\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholecystectomy is one of the most commonly performed abdominal surgical procedures. The laparoscopic approach is preferred due to documented physiologic, economic, and cosmetic benefits compared with the open approach. However, when laparoscopic cholecystectomy is not possible or cannot be completed safely, open cholecystectomy is indicated. Open cholecystectomy may also be performed as an integral part of another operation (eg, pancreaticoduodenectomy) or incidentally, if indicated, during another gastrointestinal operation (eg, colon resection). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the technique of open cholecystectomy. Laparoscopic cholecystectomy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19099996\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for a cholecystectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic cholelithiasis with or without complications (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=see_link\">",
"       \"Treatment of acute cholecystitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link\">",
"       \"Uncomplicated gallstone disease in adults\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Acalculous cholecystitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6742?source=see_link\">",
"       \"Acalculous cholecystitis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Asymptomatic cholelithiasis in patients at an increased risk for gallbladder carcinoma or gallstone complications (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"       \"Approach to the patient with incidental gallstones\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gallbladder polyps &gt;0.5 cm (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13209?source=see_link\">",
"       \"Gallbladder polyps and cholesterolosis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Porcelain gallbladder (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39668?source=see_link\">",
"       \"Porcelain gallbladder\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Incidental cholecystectomy for asymptomatic cholelithiasis may be considered when the patient is undergoing surgery for another gastrointestinal indication provided that the index operation has proceeded uneventfully, the patient is stable, and the cholecystectomy looks like it would be straightforward. In patients with asymptomatic gallstones who undergo an abdominal operation, there is a risk of developing symptomatic gallbladder disease within several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24392458\">",
"    <span class=\"h2\">",
"     Indications for open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indication for open cholecystectomy is the inability to safely or effectively complete a laparoscopic cholecystectomy in the patient with symptomatic gallstones. Other reasons to perform open cholecystectomy preferentially over laparoscopic cholecystectomy are presented below. (See",
"    <a class=\"local\" href=\"#H24392986\">",
"     'Absolute indications for open surgery'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24392993\">",
"     'Relative indications for open surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24392797\">",
"    <span class=\"h3\">",
"     Conversion from laparoscopic operation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conversion of the laparoscopic cholecystectomy to an open approach is usually performed to avoid injury to associated structures. This reflects sound surgical judgment and should not be viewed as a failure or complication of the laparoscopic approach. A conversion rate of 9.5 percent of cases was reported in The United States National Hospital Discharge Surveys, which identified one million patients who underwent cholecystectomy from 2000 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar conversion rates have been reported in other large population-based studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/4\">",
"     4",
"    </a>",
"    ]. Predictors of conversion to open cholecystectomy include age (OR 1.01 per year, 95% CI 1.01-1.02), male gender (OR 2.40, CI 1.73-3.33), emergency status (OR 1.42, CI 1.09-1.84), serum albumin",
"    <span class=\"nowrap\">",
"     (-1g/dL)",
"    </span>",
"    (OR 1.43, CI 1.26-1.62), and previous abdominal surgery (OR 1.64, CI 1.20-2.25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24392986\">",
"    <span class=\"h3\">",
"     Absolute indications for open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a laparoscopic approach is generally preferred, cholecystectomy should",
"    <strong>",
"     not",
"    </strong>",
"    be undertaken laparoscopically in some patients. Absolute indications for open surgery as the initial approach include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are unlikely to tolerate pneumoperitoneum due to hemodynamic instability or significant cardiorespiratory comorbidities. Pneumoperitoneum in a hemodynamically unstable patient or in a patient with marginal cardiopulmonary reserve may lead to cardiovascular collapse.",
"     </li>",
"     <li>",
"      Patients with refractory coagulopathy. Although coagulopathy should be corrected if possible before any operation, multiple bleeding points and generalized oozing is more easily handled in an open operation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32439?source=see_link\">",
"       \"Preoperative assessment of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are strongly suspected to have gallbladder cancer. When there is a strong suspicion for gallbladder cancer on preoperative imaging, an open approach is recommended to avoid perforation of the gallbladder and intraperitoneal dissemination of malignant cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=see_link\">",
"       \"Surgical management of gallbladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have other intraabdominal pathology requiring open surgery or who need cholecystectomy as part of another procedure (eg, Whipple procedure). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43721?source=see_link\">",
"       \"Pancreaticoduodenectomy (Whipple procedure): Techniques\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24392993\">",
"    <span class=\"h3\">",
"     Relative indications for open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative indications for open cholecystectomy as the initial approach include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have had prior upper abdominal surgery because scar tissue may preclude safe laparoscopic dissection.",
"     </li>",
"     <li>",
"      Patients with a history of a cholecysto-enteric fistula. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Cholecystoenteric fistula'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26598?source=see_link\">",
"       \"Gallstone ileus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are pregnant. Although studies report safety of laparoscopy in any trimester of pregnancy, an open approach may be needed in the third trimester due to difficulty in port placement and insufflation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=see_link\">",
"       \"Gallstone disease in pregnant women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=see_link\">",
"       \"Laparoscopic surgery in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with cirrhosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      portal hypertension in whom cholecystectomy is associated with increased operative morbidity and mortality. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=see_link\">",
"       \"Overview of the complications, prognosis, and management of cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550922\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with laparoscopic cholecystectomy, patients undergoing open cholecystectomy are generally older with more comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/5\">",
"     5",
"    </a>",
"    ]. To minimize perioperative morbidity and mortality, the patient&rsquo;s medical history should be reviewed and measures should be instituted to optimize medical comorbidities prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Specific complications of open cholecystectomy that should be discussed with the patient include possible injury to the bile duct or other portal structures (&lt;0.2 to 0.5 percent) or surrounding viscera, bile leak, retained stones, and persistent symptoms (postcholecystectomy syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6232?source=see_link\">",
"     \"Repair of common bile duct injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link&amp;anchor=H689178094#H689178094\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Postcholecystectomy syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential need for additional procedures depending upon the preoperative diagnosis should also be explained. Consent for common bile duct exploration should be obtained in patients with choledocholithiasis (suspected or proven) regardless of whether a preoperative ERCP has been performed. Patients with suspected gallbladder cancer may require more extensive surgery, which is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=see_link\">",
"     \"Surgical management of gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550929\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing in patients being evaluated for acute cholecystitis typically includes a complete blood count, liver enzymes, amylase, and lipase.",
"   </p>",
"   <p>",
"    Elevations in the serum total bilirubin and alkaline phosphatase concentrations are",
"    <strong>",
"     not",
"    </strong>",
"    common in uncomplicated cholecystitis, since biliary obstruction is limited to the gallbladder; if present, they should raise concerns about complicating conditions such as cholangitis, choledocholithiasis, or the Mirizzi syndrome (a gallstone impacted in the distal cystic duct causing extrinsic compression of the common bile duct). However, mild elevations have been reported even in the absence of these complications, and may be due to the passage of small stones, sludge, or pus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For young otherwise healthy patients with gallstones but no evidence of pericholecystic inflammation or bile duct dilation, additional preoperative lab testing is not routinely necessary, unless a new clinical event has occurred, such as significant pain, fever, or jaundice, or the physical exam suggests that an abnormality is present. An electrocardiogram or chest radiograph is obtained as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link&amp;anchor=H10#H10\">",
"     \"Preoperative medical evaluation of the healthy patient\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with complicated biliary tract disease, abnormal tests (eg, liver function tests, amylase, lipase) should be repeated to serve as a baseline for postoperative comparison. Coagulation tests are not routinely needed but may be obtained if there is a reason to believe an abnormality may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550936\">",
"    <span class=\"h2\">",
"     Preoperative imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cholelithiasis or cholecystitis will have already been established using ultrasonography, nuclear cholescintigraphy (technetium-labeled hepatic iminodiacetic acid or HIDA scan) or other advanced imaging studies such as computed tomography. These studies need not be repeated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link&amp;anchor=H7#H7\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to open cholecystectomy, we prefer preoperative endoscopic retrograde cholangiopancreatography (ERCP) in patients suspected of having biliary obstruction. ERCP with sphincterotomy and stone extraction is usually therapeutic in patients with choledocholithiasis, cholangitis, and gallstone pancreatitis with stone impaction, and can be used to rule out malignancy. If the ERCP is unsuccessful at clearing the stones, the surgeon should be prepared for an operative common bile duct exploration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6440?source=see_link\">",
"     \"Common bile duct exploration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a relatively low probability of common duct stones, magnetic resonance cholangiopancreatography (MRCP) may obviate the need for the more invasive ERCP. In patients with a high probability of common duct stones (eg, jaundice and choledocholithiasis on ultrasound), MRCP is unnecessary prior to ERCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=see_link&amp;anchor=H5#H5\">",
"     \"Magnetic resonance cholangiopancreatography\", section on 'Bile duct obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233237969\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636461232\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If available, a harmonic scalpel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an argon beam coagulator can help reduce blood loss occasionally associated during resection of the gallbladder from the liver bed in patients with coagulation abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636461246\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend antibiotic prophylaxis prior to open cholecystectomy. A systematic review identified 42 trials that randomly assigned patients undergoing open biliary tract surgery to prophylactic antibiotics versus no antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/7\">",
"     7",
"    </a>",
"    ]. A pooled analysis found a significantly reduced risk of wound infection for those who received prophylactic antibiotics (odds ratio 0.3, 95% CI 0.23-0.38). Prophylactic intravenous antibiotics should be administered within 60 minutes of the incision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=see_link\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some have questioned the need for prophylactic antibiotics prior to low risk elective cholecystectomy (cholelithiasis not associated with complications) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. However, most studies have evaluated patients undergoing laparoscopic cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, for patients undergoing low risk open cholecystectomy, we give a single dose of preoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 to 2 g (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"mobipreview.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ), which provides adequate coverage against common gram-positive skin organisms as well as the most common gram-negative organisms isolated from the biliary tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. To ensure adequate tissue levels, a dose of 2 g should be administered to patients weighing &gt;80 kg.",
"   </p>",
"   <p>",
"    Additional antimicrobial coverage is needed for patients who are undergoing emergent surgery or those who are at risk for developing infected bile such as patients with acute cholecystitis, cholangitis, jaundice, choledocholithiasis, pancreatitis, diabetes or other immunosuppressive condition, or age greater than 60 years (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"mobipreview.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ). For acute cholecystitis, second-generation cephalosporins including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    may be used. In penicillin-allergic patients, a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is an acceptable alternative. In the presence of acute cholangitis,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"      piperacillin",
"     </a>",
"     /tazobactam,",
"    </span>",
"    imipenem, or ciprofloxacin with metronidazole may be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=see_link\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636461260\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients undergoing elective open cholecystectomy for symptomatic cholelithiasis will have a low to moderate risk for thromboembolism (",
"    <a class=\"graphic graphic_table graphicRef83739 \" href=\"mobipreview.htm?22/50/23341\">",
"     table 2",
"    </a>",
"    ). Obese patients, elderly patients, and those undergoing open cholecystectomy for cancer will have a high risk for thromboembolism. We use intermittent pneumatic compression devices for all patients, and administer pharmacologic prophylaxis based upon the patient&rsquo;s level of risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H34#H34\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Group specific recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636462036\">",
"    <span class=\"h1\">",
"     GALLBLADDER ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gallbladder is a small, pear-shaped organ that is located inferior to the margin of the right lobe of the liver (",
"    <a class=\"graphic graphic_figure graphicRef71755 \" href=\"mobipreview.htm?14/48/15106\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The gallbladder is divided into distinct segments: the fundus, body, infundibulum and the neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fundus is the expanded end of the gallbladder that projects away from the margin of the liver. It is anatomically associated with the anterior abdominal wall and hepatic flexure of the colon.",
"     </li>",
"     <li>",
"      The body of the gallbladder is attached to the liver by loose connective tissue superiorly. Inferiorly, the free margin abuts the duodenum and transverse colon. Superiorly, it is anatomically associated with segments IV and V of the liver (",
"      <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The neck of the gallbladder extends from the body to the cystic duct.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cystic duct joins the common bile duct along its course from the liver to the duodenum. The level of the juncture and course of the cystic duct can vary (",
"    <a class=\"graphic graphic_figure graphicRef69483 \" href=\"mobipreview.htm?6/10/6307\">",
"     figure 3",
"    </a>",
"    ). Anatomic variations of the ductal structures include accessory hepatic ducts, a short or nonexistent cystic duct, or a cystic duct that drains into the right hepatic duct. The various configurations of accessory hepatic ducts and variations in cystic and hepatic ducts are shown in the figures (",
"    <a class=\"graphic graphic_figure graphicRef79551 \" href=\"mobipreview.htm?19/17/19743\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69483 \" href=\"mobipreview.htm?6/10/6307\">",
"     figure 3",
"    </a>",
"    ). Less common anatomic variants of the ductal anatomy occur in Caroli's disease and Caroli's syndrome. Caroli's disease is a congenital disorder characterized by multifocal, segmental dilatation of large intrahepatic bile ducts. The condition is usually associated with renal cystic disease of varying severity. Caroli initially described two variants, which has led to some confusion in terminology. Caroli's disease is the less common form and is characterized by bile ductular ectasia without other apparent hepatic abnormalities. The more common variant is Caroli's syndrome in which bile duct dilatation is associated with congenital hepatic fibrosis. Caroli's disease and syndrome are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2902?source=see_link\">",
"     \"Caroli disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gallbladder is supplied by the cystic artery, which is usually a branch of the right hepatic artery; however, the cystic artery or an accessory cystic artery can arise from the right hepatic, left hepatic, or common hepatic artery. The cystic artery courses along the cystic duct and divides at the neck of the gallbladder into superficial and deep branches, which supply in the",
"    <span class=\"nowrap\">",
"     anterior/inferior",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     posterior/superior",
"    </span>",
"    aspects of the gallbladder, respectively. The venous drainage of the gallbladder generally parallels the course of the arteries draining into the cystic vein, which drains into the gallbladder fossa directly into the right hepatic vein (ie, it does not accompany the cystic artery). Anatomic variations of the origin and course of the cystic artery are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef56280 \" href=\"mobipreview.htm?18/3/18481\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19100056\">",
"    <span class=\"h1\">",
"     OPEN CHOLECYSTECTOMY PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open cholecystectomy is typically performed under general anesthesia through a right upper quadrant incision. Cholecystectomy under regional anesthesia has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the patient is anesthetized, he or she is positioned supine on the operating table with arms extended laterally to facilitate placement of self-retaining retractors. The general principles for performing open cholecystectomy are discussed below and are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef73464 \" href=\"mobipreview.htm?12/54/13160\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162641\">",
"    <span class=\"h2\">",
"     Exposing the gallbladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common approach for open cholecystectomy is through a right subcostal incision, extending obliquely from the midline, parallel to and 2 to 3 cm inferior to the right costal margin. Gallbladder exposure is optimized by completely dividing the right rectus abdominis muscle and incising the linea alba. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=see_link&amp;anchor=H3294660#H3294660\">",
"     \"Principles of abdominal wall incisions\", section on 'Subcostal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients undergoing conversion from a laparoscopic approach to an open approach, the subcostal incision can be made by connecting the subxiphoid and medial subcostal port-site incisions (",
"    <a class=\"graphic graphic_figure graphicRef50974 \" href=\"mobipreview.htm?33/14/34018\">",
"     figure 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link&amp;anchor=H17#H17\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Conventional port placement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A midline incision can also provide adequate exposure for open cholecystectomy and is preferred in patients undergoing a concomitant abdominal or pelvic procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=see_link&amp;anchor=H15#H15\">",
"     \"Principles of abdominal wall incisions\", section on 'Midline incision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the incision is made, moist sponges and retractors are placed (handheld or self-retaining) to retract the hepatic flexure of the colon inferiorly, the duodenum medially, and the liver superiorly. Care is taken to avoid injury to surrounding organs, particularly in the setting of acute or chronic inflammation. Exposure may sometimes be improved by decompressing the gallbladder, which can be performed by making a small incision in the gallbladder fundus, suctioning out the bile and suturing the defect closed to prevent subsequent spillage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H744709095\">",
"    <span class=\"h2\">",
"     Gallbladder dissection and removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although laparoscopic cholecystectomy is most often performed &ldquo;bottom-up&rdquo; starting from the infundibulum of the gallbladder, many surgeons perform open cholecystectomy &ldquo;top-down&rdquo; starting from the fundus of the gallbladder. The top-down approach frees the gallbladder from the liver first, leaving the cystic duct as the only remaining attachment, which can be divided without requiring dissection more medially, potentially minimizing the likelihood of injury to the portal structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233235781\">",
"    <span class=\"h3\">",
"     Top-down approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A top-down approach can be a good alternative if there is any uncertainty about the location of the cystic duct and cystic artery in relation to other structures in the hilum of the liver. However, chronic inflammation can tether the gallbladder to the right-sided hilar structures and lead to complications with this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/17\">",
"     17",
"    </a>",
"    ]. A small contracted intrahepatic gallbladder may be indicative of this possibility. Prior to dissecting the gallbladder, it may be useful to identify the cystic duct and artery and doubly loop them with suture or small vessel loops. The fundus of the gallbladder is grasped and retracted away from the liver. The plane between the gallbladder and liver is divided using electrocautery. Dissection is continued until the gallbladder is freed from the liver bed. Any bleeding from the liver bed can usually be controlled with direct pressure or electrocautery. Argon beam coagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suture ligation of visible vessels may be useful in some cases, but deep suturing into the liver should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14984?source=see_link&amp;anchor=H9#H9\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\", section on 'Electrosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The structures entering the gallbladder are dissected from the surrounding connective tissue and fat, identifying the cystic duct entering the base of the gallbladder and the cystic arteries. The cystic artery or arteries can be ligated close to the gallbladder wall. The cystic duct should be milked toward the gallbladder to remove debris, and then it is ligated. It is not necessary to dissect the cystic",
"    <span class=\"nowrap\">",
"     duct/common",
"    </span>",
"    duct junction and, in the setting of severe inflammation or obliteration of tissue planes, it is acceptable to leave some gallbladder attached to the cystic duct. If this option is necessary, the residual gallbladder remnant should be cleared of debris and closed securely. Once the cystic duct has been divided and ligated, the gallbladder is removed from the field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1233235833\">",
"    <span class=\"h3\">",
"     Bottom-up approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unequivocal identification of the cystic duct and cystic artery is important for avoiding injury to the portal structures. The cystic duct should",
"    <strong>",
"     not",
"    </strong>",
"    be clipped or divided until the surgeon is certain that the putative cystic duct goes directly into the gallbladder, and that there are no other ductal structures coursing between the base of the gallbladder and the liver bed. An &ldquo;anomalous&rdquo; cystic duct or cystic artery&nbsp;should",
"    <strong>",
"     not",
"    </strong>",
"    be divided until the surgeon is&nbsp;absolutely certain that the structure is not a major duct or artery. If there is any question regarding ductal anatomy, intrahepatic cholangiography should be performed. (See",
"    <a class=\"local\" href=\"#H1162683\">",
"     'Intraoperative cholangiography'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    For a bottom-up approach, retraction and dissection of the gallbladder is similar to laparoscopic cholecystectomy. The fundus of the gallbladder is grasped with a clamp and retracted cranially. This helps expose the infundibulum of the gallbladder. The infundibulum is grasped and retracted laterally and inferiorly. With the gallbladder retracted in this manner, the cystic duct and artery will straighten, which facilitates dissection in the triangle of Calot, (bounded by the cystic duct inferiorly, the cystic artery superiorly and the common hepatic duct medially), to obtain the &ldquo;critical view of safety&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef66207 \" href=\"mobipreview.htm?25/3/25649\">",
"     figure 8",
"    </a>",
"    ), which must be achieved prior to clipping or ligating the cystic duct and cystic artery and when accomplished, the structures seen entering the gallbladder can only be the cystic duct and artery, and thus, injury to major structures is avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. To achieve the &ldquo;critical view of safety&rdquo;, a term originally adopted to describe the proper camera view during laparoscopic cholecystectomy, the triangle of Calot is dissected free of all connective tissue and fat exposing the cystic duct and cystic artery, and the medial margin of the gallbladder is freed from the liver. It is not necessary to routinely open the peritoneum over the common duct, but the surgeon should be confident about the location of the common duct where the putative cystic duct drains into it. The dissection begins at the level of the infundibulum. The peritoneum over the infundibulum of the gallbladder is bluntly dissected and the peritoneum stripped along the cystic duct. An unusually large cystic duct should prompt the surgeon to re-evaluate the anatomy. Once the cystic duct has been identified with certainty, its contents should be gently \"milked\" toward the gallbladder and if substantial debris is suspected, a doubly looped silk suture (Pott&rsquo;s tie) can be placed around the cystic duct and held under gentle tension to prevent the debris from passing distally during subsequent gallbladder manipulation, which can lead to postcholecystectomy complications or choledocholithiasis. After the cystic duct has been dissected, the cystic artery, which usually has anterior and posterior branches, is located. The cystic artery branches can often be unequivocally identified entering the gallbladder where they can be ligated prior to freeing the gallbladder from the liver bed. Otherwise, it should be secured with a double loop of silk suture and temporarily occluded while the gallbladder is freed from the liver bed. If there is concern that the structure could be a diminutive right hepatic artery, a vessel loop can be used for temporary occlusion. Once the dissection is completed and the cystic duct and artery have been identified with certainty, they are ligated and the gallbladder removed.",
"   </p>",
"   <p>",
"    Dissection of the gallbladder from the liver is accomplished by retracting the gallbladder from the liver and dividing the tissue in the plane between the gallbladder and liver using electrocautery. Any bleeding from the liver bed can usually be controlled with direct pressure or electrocautery. Argon beam coagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suture ligation of visible vessels may be useful in some cases, but deep suturing into the liver should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14984?source=see_link&amp;anchor=H9#H9\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\", section on 'Electrosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396555\">",
"    <span class=\"h3\">",
"     Unusual situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unusual situations are sometimes encountered during cholecystectomy. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrahepatic gallbladder &ndash; Intrahepatic gallbladder can be removed in the usual fashion. Rarely, it is necessary to leave the back wall of the gallbladder on the liver bed to avoid a difficult dissection and excessive bleeding from the liver. In this setting, the mucosa should be obliterated with electrocautery or argon beam coagulation.",
"     </li>",
"     <li>",
"      Inability to safely perform cholecystectomy &ndash; If an open cholecystectomy is started and difficulties are encountered, conversion to a cholecystostomy may be useful, provided the gallbladder has not been devascularized. (See",
"      <a class=\"local\" href=\"#H1162878\">",
"       'Open cholecystostomy tube placement'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Gallbladder fistula &ndash; Gallbladder fistulae are rare, and typically involve the duodenum, stomach, colon, or common bile duct. Once the gallbladder is separated, intestinal defects are usually closed primarily. Fistulous connections to the extrahepatic biliary tree, such as with Mirizzi syndrome, may be adequately managed with T-tube insertion into the biliary defect, but may require ductal reconstruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26598?source=see_link&amp;anchor=H7#H7\">",
"       \"Gallstone ileus\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=see_link&amp;anchor=H7#H7\">",
"       \"Mirizzi syndrome\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gallbladder cancer &ndash; Gallbladder cancer is rare, but a suspicion may be raised during the course of cholecystectomy. An appropriately trained hepatobiliary surgeon may proceed with extended cholecystectomy or more radical procedure. Those surgeons with less experience can complete the cholecystectomy and await the results of final pathology to determine the next course of treatment, which may be referral to a tertiary center for re-resection. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=see_link\">",
"       \"Surgical management of gallbladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162683\">",
"    <span class=\"h2\">",
"     Intraoperative cholangiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute indications for intraoperative cholangiography during open cholecystectomy include unclear ductal anatomy, jaundice, and stones in the biliary tree suspected by palpation or preoperative imaging. Intraoperative ultrasound may be equivalent to cholangiography in diagnostic accuracy for common duct stones in experienced hands. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link&amp;anchor=H972628573#H972628573\">",
"     \"Approach to the patient with suspected choledocholithiasis\", section on 'Intraoperative ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is doubt about the ductal anatomy, injection of contrast into the gallbladder using a needle may be preferable to ductotomy and clip occlusion of (what may turn out to be) an important ductal structure. Ideally, the anatomy should be clarified before any ductotomy is made, but if this is not possible, the ductal opening for the cholangiogram catheter should be small in case what is thought to be the cystic duct turns out to be the common duct or a lobar duct.",
"     </li>",
"     <li>",
"      Real-time imaging with fluoroscopy is preferred to static radiography. Glucagon (1 mg intravenously) may be needed to relax the ampulla of Vater to facilitate contrast flow into the duodenum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550031\">",
"    <span class=\"h2\">",
"     Common bile duct exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If cholangiography confirms the presence of common bile duct stones and postoperative ERCP with stone extraction is not a likely option (eg, Roux-en-Y gastric bypass, prior failed ERCP, lack of local expertise), common bile duct exploration and removal of stones will be necessary. The procedure of common bile duct exploration is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6440?source=see_link\">",
"     \"Common bile duct exploration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162947\">",
"    <span class=\"h2\">",
"     Closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the cholecystectomy is completed, the region of the dissection should be irrigated and drained, and examined for evidence of bleeding or biliary leak (eg, liver bed, cystic duct stump).",
"   </p>",
"   <p>",
"    Routine drainage of the peritoneal cavity after cholecystectomy is",
"    <strong>",
"     not",
"    </strong>",
"    indicated because it increases wound infection rates and delays hospital discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. However, it is acceptable to selectively drain the peritoneal cavity after a difficult cholecystectomy, or if there is evidence of residual bile leakage from the liver bed. Drains are not a substitute for adequate hemostasis and cannot be relied upon to indicate the extent of, or the absence of, postoperative hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/23\">",
"     23",
"    </a>",
"    ]. When drains are employed, closed suction drains should be used and the drain(s) should be brought through a separate stab wound, rather than through the surgical incision, which may compromise incisional healing.",
"   </p>",
"   <p>",
"    Although the subcostal incision is resistant to dehiscence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    herniation, healing may be compromised by poor technique. When closing the right subcostal incision, most surgeons approximate the fascia in two layers. Care should be taken to ensure incorporation of the appropriate tissue layers lateral to the border of the rectus muscle. Single-layer mass closure is acceptable, particularly when the posterior fascia will not hold suture well. The principles of surgical wound closure are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162878\">",
"    <span class=\"h1\">",
"     OPEN CHOLECYSTOSTOMY TUBE PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;To place a cholecystotomy tube, a pursestring suture is placed into the fundus of the gallbladder through which an 18 F balloon catheter (inflated once inside the gallbladder) or mushroom catheter is introduced after making a stab incision within the confines of the pursestring suture. The pursestring suture is drawn up and tied to secure the catheter. The catheter should be brought out of the abdomen through a site separate from the abdominal incision. The gallbladder wall is sutured to the peritoneum where the catheter exits the abdomen. If the gallbladder cannot be brought up to the abdominal wall, the space between the gallbladder and abdominal wall should be buttressed with omentum and closed-suction drains placed.",
"   </p>",
"   <p>",
"    The cholecystostomy tube is placed to gravity drainage and should be irrigated with small quantities of sterile saline, as needed. After one week, cholangiography can be performed through the cholecystostomy tube. The cholecystostomy tube can be clamped in two to three weeks, and if tolerated, the tube can be removed one month after placement, provided there is no ongoing need for the tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19100129\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an uncomplicated open cholecystectomy, patients can drink clear liquids once awake from anesthesia and their diet can be advanced as tolerated. Incentive inspirometry and early ambulation should be encouraged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients undergoing open cholecystectomy will require a minimum of one to two days in the hospital to assure adequate pain control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If pharmacologic deep vein thrombosis (DVT) prophylaxis is used, we avoid the use of non-steroidal antiinflammatory agents (NSAIDs) such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    because of the potential increased risk for postoperative bleeding.",
"   </p>",
"   <p>",
"    Routine postoperative laboratory studies are not necessary unless complications such as bleeding, infection, bile leak, choledocholithiasis, or pancreatitis are suspected. Antibiotics should be discontinued within 24 hours unless there is evidence or suspicion of ongoing infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nasogastric tube that is placed in the operating room can be discontinued in the postanesthesia care unit. If the patient is refractory to anti-emetic medications, the nasogastric tube can be replaced.",
"   </p>",
"   <p>",
"    Following discharge from the hospital, the patient should see the operating surgeon around two and six weeks postoperatively. At these intervals, patients are evaluated for signs and symptoms of infection, biliary complications, and wound problems. Following open cholecystectomy, most patients are feeling quite well at two weeks (minimal narcotic use and improving appetite) and are usually fully recovered at six weeks. Failure to progress accordingly may be indicative of postoperative complications. (See",
"    <a class=\"local\" href=\"#H19100136\">",
"     'Perioperative morbidity and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The patient may develop problems with dyspepsia and possibly persistent abdominal discomfort following gallbladder removal, a constellation of symptoms known as the postcholecystectomy syndrome (PCS). This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link&amp;anchor=H689178094#H689178094\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Postcholecystectomy syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19100136\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open cholecystectomy is associated with significant morbidity and mortality, which is not surprising given that open cholecystectomy is more often performed for complicated biliary tract disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Compared with laparoscopic cholecystectomy, a study from the National Surgical Quality Improvement Program (ACS NSQIP) database found that patients who underwent open surgery were older with a higher comorbidity burden and had higher rates of mortality (2.8 versus 0.3 percent), infection (8.4 versus 1.3 percent), and other serious complications (11 versus 1.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications related to cholecystectomy can be systemic, related to patient comorbidities or anesthetic technique, or related directly to the cholecystectomy. The most common systemic complications are pulmonary in nature. An observational study of 2139 patients who underwent either open cholecystectomy or were converted to open cholecystectomy reported failure to wean off the ventilator after more than 48 hours in 4.7 percent, unplanned intubation in 3.4 percent, pneumonia in 3.6 percent, and pulmonary embolism in 0.3 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/4\">",
"     4",
"    </a>",
"    ]. Atelectasis and more serious postoperative pulmonary complications can be prevented in some cases by early ambulation, incentive spirometry, and analgesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=see_link\">",
"     \"Overview of the management of postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications specifically related to the surgical procedure include bleeding, bile leak (which may be related to ductal injury), and infection (surgical site or intraabdominal). These are discussed below.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636462938\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant bleeding during cholecystectomy is unusual in patients who do not have coagulation abnormalities (eg, cirrhosis). Hemodynamically stable patients may be observed initially; however, postoperative bleeding associated with hemodynamic instability should prompt abdominal exploration.",
"   </p>",
"   <p>",
"    Major bile duct injury may be associated with injury to associated vessels, most commonly, the right hepatic artery. In the setting of severe acute or chronic inflammation, inadvertently dissecting the common bile duct can also lead to injury of the portal vein.",
"   </p>",
"   <p>",
"    If a major vascular injury is recognized during an open cholecystectomy, primary repair should be performed by an experienced vascular, hepatobiliary, or liver transplant surgeon. Following repair, duplex imaging should be used to confirm patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636462838\">",
"    <span class=\"h2\">",
"     Bile leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile leak due to major bile duct injury following open cholecystectomy is rare; bile leaks are more commonly related to the liver bed or cystic duct stump. If a major ductal injury is found, in the absence of a surgeon appropriately trained in advanced hepatobiliary surgery, transfer to a tertiary center is appropriate.",
"   </p>",
"   <p>",
"    If a drain has been placed during the cholecystectomy procedure, bilious drainage in the postoperative period is obvious. In those patients who have not had a drain placed, a bile leak should be suspected if postoperative progress is delayed. Common symptoms include persistent abdominal pain, ileus, fever, and hyperbilirubinemia. The bile leak may be from the liver bed (duct of Luschka), cystic duct stump (displaced clip or suture), or, rarely, due to an extrahepatic biliary ductal injury. Ultrasound or computed tomography (CT) of the abdomen may show a substantial subhepatic, perihepatic, or, sometimes, free intraperitoneal fluid. The choice of initial postoperative study depends upon the clinical scenario and urgency. Although CT scan of the abdomen shows more detail, abdominal ultrasound is generally quicker to obtain and does not require contrast administration.",
"   </p>",
"   <p>",
"    Biliary scintigraphy (technetium labeled hepatic iminodiacetic acid [HIDA] scan) or ERCP can be used to confirm bile extravasation. Major ductal injury (eg, transection of the common bile duct, hepatic ducts) should be suspected on the basis of HIDA scan or ERCP. Worrisome findings include extravasation of isotope and nonvisualization of bowel on HIDA scan, and failure to visualize the proximal common duct or lobar branches on ERCP. If the bowel &ldquo;lights up&rdquo; on HIDA scan, this confirms that there is at least partial ductal continuity between the liver and duodenum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6232?source=see_link\">",
"     \"Repair of common bile duct injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the source of bile leak and amount of drainage determine the next course of therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low output bile leak (ducts of Luschka) can generally be treated with drainage alone (percutaneous drainage if intraoperative drainage was not provided).",
"     </li>",
"     <li>",
"      Substantial leakage from the liver bed or cystic duct stump can initially be treated with drainage and temporary endoscopic stenting of the ampulla of Vater to reduce biliary pressure. Reoperation may be needed to provide better drainage or repair the cystic duct.",
"     </li>",
"     <li>",
"      Rarely, an aberrant right segmental or sectoral duct has a very low insertion into the biliary tree and is prone to injury during cholecystectomy (",
"      <a class=\"graphic graphic_figure graphicRef79551 \" href=\"mobipreview.htm?19/17/19743\">",
"       figure 4",
"      </a>",
"      ). If the severed aberrant duct is left open (Strasberg type C injury), a postoperative bile leak is evident and typically it is refractory to ERCP stenting since there is discontinuity between the leaking duct and the common bile duct. Ligation of aberrant right sectoral ducts (Strasberg type B injury) is typically well tolerated if the duct is small and drains only one hepatic segment or less, and the biliary tree is sterile. Otherwise, biliary reconstruction is necessary.",
"     </li>",
"     <li>",
"      Management of transection of more major biliary ducts (eg, common bile duct) is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6232?source=see_link\">",
"       \"Repair of common bile duct injuries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18792?source=see_link&amp;anchor=H11#H11\">",
"       \"Complications of laparoscopic cholecystectomy\", section on 'Biliary and cystic duct leaks'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636463088\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious complications associated with open cholecystectomy include surgical site infection, and intraabdominal abscess typically, which may be related to bile leak",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematoma.",
"   </p>",
"   <p>",
"    In a study of 2139 patients who underwent either open cholecystectomy or were converted to open cholecystectomy, superficial wound infections occurred in 5.4 percent of patients, deep wound infections in 1 percent, and wound dehiscence in 1 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/40/36489/abstract/4\">",
"     4",
"    </a>",
"    ]. Wound infections are treated with antibiotics and open drainage, as needed. The prevention and treatment of wound infections and urinary tract infections is discussed elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1163908\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common indication for open cholecystectomy is the inability to safely",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      effectively complete a laparoscopic cholecystectomy in the patient with symptomatic gallstones. Conversion to an open operation from laparoscopic cholecystectomy is performed when laparoscopic dissection is difficult, gallbladder cancer or a cholecystenteric fistula is identified, the anatomy is not well defined, or intraoperative complications arise. (See",
"      <a class=\"local\" href=\"#H24392797\">",
"       'Conversion from laparoscopic operation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open cholecystectomy should be planned in patients who are unable to tolerate pneumoperitoneum, patients with coagulopathy, patients who are suspected to have gallbladder cancer, and critically ill patients who require open surgery for other intraabdominal pathology. (See",
"      <a class=\"local\" href=\"#H24392458\">",
"       'Indications for open surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open cholecystectomy is typically performed under general anesthesia through a right upper quadrant incision. Open cholecystectomy can be performed using a &ldquo;top-down&rdquo; approach, starting from the fundus of the gallbladder, or a &ldquo;bottom-up&rdquo; approach, starting from the infundibulum of the gallbladder. Using a &ldquo;bottom-up&rdquo; approach, the unequivocal identification of the cystic duct and cystic artery is essential to avoid ductal injuries. The advantage of the &ldquo;top-down&rdquo; approach is that it frees the gallbladder from the liver first, leaving the cystic duct and artery as the only remaining attachments; however, chronic inflammation can tether the gallbladder to the right-sided hilar structures making a &ldquo;top-down&rdquo; approach difficult. (See",
"      <a class=\"local\" href=\"#H744709095\">",
"       'Gallbladder dissection and removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for intraoperative cholangiography during open cholecystectomy include unclear ductal anatomy, jaundice, and stones in the biliary tree suspected by palpation or preoperative imaging. If cholangiography confirms the presence of common bile duct stones and postoperative ERCP is not a likely option, common bile duct exploration and removal of stones will be necessary. (See",
"      <a class=\"local\" href=\"#H1162683\">",
"       'Intraoperative cholangiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H550031\">",
"       'Common bile duct exploration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following uneventful open cholecystectomy, most patients are feeling quite well at two weeks (minimal narcotic use and improving appetite) and are usually fully recovered at six weeks. Failure to progress accordingly may be indicative of postoperative complications. (See",
"      <a class=\"local\" href=\"#H19100129\">",
"       'Postoperative care and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications related to cholecystectomy can be systemic, related to patient comorbidities or anesthetic technique, or related directly to the cholecystectomy. The most common systemic complications are pulmonary in nature. Complications specifically related to the surgical procedure include bleeding, bile leak (which may be related to ductal injury), and infection (surgical site or intraabdominal). (See",
"      <a class=\"local\" href=\"#H19100136\">",
"       'Perioperative morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bile leak should be suspected in patients who do not progress normally after cholecystectomy. Common symptoms include persistent abdominal pain, ileus, fever, and hyperbilirubinemia. Ultrasound or computed tomography of the abdomen may be used in the initial evaluation of bile leak, and suspected leak confirmed using biliary scintigraphy (HIDA scan) or ERCP. The management of bile leak following open cholecystectomy depends upon the amount and source of the leak. (See",
"      <a class=\"local\" href=\"#H636462838\">",
"       'Bile leak'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/1\">",
"      Bragg LE, Thompson JS. Concomitant cholecystectomy for asymptomatic cholelithiasis. Arch Surg 1989; 124:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/2\">",
"      Juhasz ES, Wolff BG, Meagher AP, et al. Incidental cholecystectomy during colorectal surgery. Ann Surg 1994; 219:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/3\">",
"      Csikesz N, Ricciardi R, Tseng JF, Shah SA. Current status of surgical management of acute cholecystitis in the United States. World J Surg 2008; 32:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/4\">",
"      Kaafarani HM, Smith TS, Neumayer L, et al. Trends, outcomes, and predictors of open and conversion to open cholecystectomy in Veterans Health Administration hospitals. Am J Surg 2010; 200:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/5\">",
"      Ingraham AM, Cohen ME, Ko CY, Hall BL. A current profile and assessment of north american cholecystectomy: results from the american college of surgeons national surgical quality improvement program. J Am Coll Surg 2010; 211:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/6\">",
"      Jenkins JT, Williamson BW. Prospective study to develop an algorithm for investigation by endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography. ANZ J Surg 2006; 76:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/7\">",
"      Meijer WS, Schmitz PI, Jeekel J. Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg 1990; 77:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/8\">",
"      Lundstr&ouml;m P, Sandblom G, Osterberg J, et al. Effectiveness of prophylactic antibiotics in a population-based cohort of patients undergoing planned cholecystectomy. J Gastrointest Surg 2010; 14:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/9\">",
"      Darkahi B, Videhult P, Sandblom G, et al. Effectiveness of antibiotic prophylaxis in cholecystectomy: a prospective population-based study of 1171 cholecystectomies. Scand J Gastroenterol 2012; 47:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/10\">",
"      Sanabria A, Dominguez LC, Valdivieso E, Gomez G. Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomy. Cochrane Database Syst Rev 2010; :CD005265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/11\">",
"      Choudhary A, Bechtold ML, Puli SR, et al. Role of prophylactic antibiotics in laparoscopic cholecystectomy: a meta-analysis. J Gastrointest Surg 2008; 12:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/12\">",
"      Lee WJ, Chang KJ, Lee CS, Chen KM. Surgery in cholangitis: bacteriology and choice of antibiotic. Hepatogastroenterology 1992; 39:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/13\">",
"      Kanter MA, Geelhoed GW. Biliary antibiotics: clinical utility in biliary surgery. South Med J 1987; 80:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/14\">",
"      Lewis RT, Goodall RG, Marien B, et al. Biliary bacteria, antibiotic use, and wound infection in surgery of the gallbladder and common bile duct. Arch Surg 1987; 122:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/15\">",
"      Pilgrim CH, Usatoff V, Evans P. Consideration of anatomical structures relevant to the surgical strategy for managing gallbladder carcinoma. Eur J Surg Oncol 2009; 35:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/16\">",
"      Savas JF, Litwack R, Davis K, Miller TA. Regional anesthesia as an alternative to general anesthesia for abdominal surgery in patients with severe pulmonary impairment. Am J Surg 2004; 188:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/17\">",
"      Strasberg SM, Gouma DJ. 'Extreme' vasculobiliary injuries: association with fundus-down cholecystectomy in severely inflamed gallbladders. HPB (Oxford) 2012; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/18\">",
"      Avgerinos C, Kelgiorgi D, Touloumis Z, et al. One thousand laparoscopic cholecystectomies in a single surgical unit using the \"critical view of safety\" technique. J Gastrointest Surg 2009; 13:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/19\">",
"      Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 1995; 180:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/20\">",
"      Gurusamy KS, Samraj K, Mullerat P, Davidson BR. Routine abdominal drainage for uncomplicated laparoscopic cholecystectomy. Cochrane Database Syst Rev 2007; :CD006004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/21\">",
"      Lewis RT, Goodall RG, Marien B, et al. Simple elective cholecystectomy: to drain or not. Am J Surg 1990; 159:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/22\">",
"      Monson JR, Guillou PJ, Keane FB, et al. Cholecystectomy is safer without drainage: the results of a prospective, randomized clinical trial. Surgery 1991; 109:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/40/36489/abstract/23\">",
"      Zaydfudim V, Russell RT, Feurer ID, et al. Drain use after open cholecystectomy: is there a justification? Langenbecks Arch Surg 2009; 394:1011.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15096 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36489=[""].join("\n");
var outline_f35_40_36489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1163908\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1162120\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19099996\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24392458\">",
"      Indications for open surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24392797\">",
"      - Conversion from laparoscopic operation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24392986\">",
"      - Absolute indications for open surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24392993\">",
"      - Relative indications for open surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550922\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550929\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550936\">",
"      Preoperative imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1233237969\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636461232\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636461246\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636461260\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H636462036\">",
"      GALLBLADDER ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19100056\">",
"      OPEN CHOLECYSTECTOMY PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1162641\">",
"      Exposing the gallbladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H744709095\">",
"      Gallbladder dissection and removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1233235781\">",
"      - Top-down approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1233235833\">",
"      - Bottom-up approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17396555\">",
"      - Unusual situations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1162683\">",
"      Intraoperative cholangiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550031\">",
"      Common bile duct exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1162947\">",
"      Closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1162878\">",
"      OPEN CHOLECYSTOSTOMY TUBE PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19100129\">",
"      POSTOPERATIVE CARE AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19100136\">",
"      PERIOPERATIVE MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636462938\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636462838\">",
"      Bile leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636463088\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1163908\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15096|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/48/15106\" title=\"figure 1\">",
"      Gallbladder anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/35/13878\" title=\"figure 2\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/10/6307\" title=\"figure 3\">",
"      Variations in the cystic and hepatic ducts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/17/19743\" title=\"figure 4\">",
"      Accessory hepatic ducts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/3/18481\" title=\"figure 5\">",
"      Variations in the origin and course of the cystic artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/54/13160\" title=\"figure 6\">",
"      Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/14/34018\" title=\"figure 7\">",
"      Port placement for laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/3/25649\" title=\"figure 8\">",
"      Critical view of safety in laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/50/23341\" title=\"table 2\">",
"      Caprini risk assessment model",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6742?source=related_link\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2902?source=related_link\">",
"      Caroli disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6440?source=related_link\">",
"      Common bile duct exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14984?source=related_link\">",
"      Devices for dissection and hemostasis in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13209?source=related_link\">",
"      Gallbladder polyps and cholesterolosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=related_link\">",
"      Gallstone disease in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26598?source=related_link\">",
"      Gallstone ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43721?source=related_link\">",
"      Pancreaticoduodenectomy (Whipple procedure): Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39668?source=related_link\">",
"      Porcelain gallbladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6232?source=related_link\">",
"      Repair of common bile duct injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=related_link\">",
"      Surgical management of gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_40_36490="Mild acute rejection";
var content_f35_40_36490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68676%7EGAST%2F62340%7EGAST%2F74100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68676%7EGAST%2F62340%7EGAST%2F74100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ITx mild acute rejection (high power view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mononuclear inflammatory infiltrate is present with crypt inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Farrukh Khan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ITx severe acute rejection (low power view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loss of surface epithelium with denudation of the mucosa layer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Farrukh Khan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe acute rejection of the ITx graft (high power view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Farrukh Khan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36490=[""].join("\n");
var outline_f35_40_36490=null;
var title_f35_40_36491="Genetic markers in IDDM";
var content_f35_40_36491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Importance of genetic markers in susceptibility to type 1 diabetes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Genetic marker",
"       </td>",
"       <td class=\"subtitle1\">",
"        No IDDM relative",
"       </td>",
"       <td class=\"subtitle1\">",
"        First degree relative with IDDM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DQB*0302/*0201",
"       </td>",
"       <td>",
"        1 in 25",
"       </td>",
"       <td>",
"        1 in 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DQB*0302/*0302",
"       </td>",
"       <td>",
"        1 in 60",
"       </td>",
"       <td>",
"        1 in 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DQB*0302/*0602",
"       </td>",
"       <td>",
"        1 in 1500",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DQB*0302/Other",
"       </td>",
"       <td>",
"        1 in 60",
"       </td>",
"       <td>",
"        1 in 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DQB*0201/*0201",
"       </td>",
"       <td>",
"        1 in 350",
"       </td>",
"       <td>",
"        1 in 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DQB*0201/*Other",
"       </td>",
"       <td>",
"        1 in 400",
"       </td>",
"       <td>",
"        1 in 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        1",
"in 5000",
"       </td>",
"       <td>",
"        1 in 40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Risk estimates for susceptibility to type 1 diabetes in Caucasians according to presence or absence of IDDM susceptibility genes and family history. DQB*0302 and DQB*0201 are associated with high susceptibility, while DQB*0602 is a protective gene. The risk is highest in patients who are heterozygous for both high susceptbility genes - DQB*0302 and DQB*0201.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331:1428.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36491=[""].join("\n");
var outline_f35_40_36491=null;
var title_f35_40_36492="Cluster for aeroallergen SCIT";
var content_f35_40_36492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aeroallergen subcutanous immunotherapy (SCIT) - Example of a cluster protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Visit number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume (ml)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dilution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Color vial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        Green",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        Green",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        2",
"       </td>",
"       <td>",
"        0.20",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.07",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        3",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.15",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        5",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.10",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        6",
"       </td>",
"       <td>",
"        0.15",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.20",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        7",
"       </td>",
"       <td>",
"        0.30",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36492=[""].join("\n");
var outline_f35_40_36492=null;
var title_f35_40_36493="R-CODOX-M IVAC regimen";
var content_f35_40_36493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    R-CODOX-M/IVAC (Magrath) regimen for Burkitt lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The R-CODOX-M/IVAC regimen is composed of four cycles, each cycle lasting until the absolute neutrophil count returns to &gt;1000/microL and the platelet count &gt;100,000/microL. Cycles 1 and 3 are R-CODOX-M and cycles 2 and 4 are R-IVAC. Three cycles of R-CODOX-M are sufficient for patients with low-risk disease (ie, a single focus of disease &lt;10 cm in diameter and a normal serum lactate",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         dehydrogenase",
"        </span>",
"        level).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        R-CODOX-M (cycles one and three):",
"        <sup>",
"         [1-4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rituximab 375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide 800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide 200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV on days 2 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin 40 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        slow IV push on day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine 1.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        (maximum 2 mg) IV on days 1 and 8 (cycle 1) and days 1, 8, and 15 (cycle 3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Age 65 years or younger: 300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV loading dose over one hour on day 10, followed by&nbsp;2700 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV infusion&nbsp;administered over&nbsp;the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Age &gt;65 years: 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV loading dose over one hour on day 10, followed by 900 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV infusion&nbsp;administered over&nbsp;the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulocyte colony-stimulating factor begins 24 hours after leucovorin rescue is started and continues until the absolute neutrophil count is &gt;1000/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Intrathecal medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intrathecal cytarabine 70 mg (if &gt;3 years of age) on days 1 and 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intrathecal methotrexate 12 mg (if &gt;3 years of age) on day 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oral leucovorin 15 mg/dose on day 16, 24 hours after intrathecal methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Enhanced CNS directed therapy for patients with CNS disease at presentation: cytarabine 70 mg/dose (if &gt;3 years of age) intrathecal (or 15 mg if via Ommaya reservoir) on day 5 and methotrexate 12 mg (if &gt;3 years of age) intrathecal (or 2 mg if via Ommaya reservoir) on day 17 in cycle 1",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        R-IVAC (cycles two and four):",
"        <sup>",
"         [1-4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rituximab 375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV on day 1&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Age 65 years or younger: 1500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV on days 1 through 5 with mesna uroprotection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Age &gt;65 years: 1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV on days 1 through 5 with mesna uroprotection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV on days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Age 65 years or younger: 2 g/m",
"        <sup>",
"         2",
"        </sup>",
"        IV every 12 hours on days 1 and 2 (four doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Age &gt;65 years:&nbsp;1 g/m",
"        <sup>",
"         2",
"        </sup>",
"        IV every 12 hours on days 1 and 2 (four doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulocyte colony-stimulating factor begins 24 hours after the completion of IV chemotherapy and continues until the absolute neutrophil count is &gt;1000/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Intrathecal medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intrathecal methotrexate 12 mg (if &gt;3 years of age) on day 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oral leucovorin 15 mg on day 6, 24 hours after intrathecal methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Enhanced CNS directed therapy for patients with CNS disease at presentation: cytarabine 70 mg (if &gt;3 years of age) intrathecal (or 15 mg if via Ommaya reservoir) on days 7 and 9 in cycle 2",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14:925.",
"       </li>",
"       <li>",
"        Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 Study. Ann Oncol 2002; 13:1264.",
"       </li>",
"       <li>",
"        Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 Trial). Blood 2008; 112:2248.",
"       </li>",
"       <li>",
"        Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45:761.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36493=[""].join("\n");
var outline_f35_40_36493=null;
var title_f35_40_36494="Classification jaundice I";
var content_f35_40_36494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Classification of jaundice due to mainly unconjugated hyperbilirubinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36494=[""].join("\n");
var outline_f35_40_36494=null;
var title_f35_40_36495="Mass and comedo";
var content_f35_40_36495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mammogram clustered calcifications A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spot compression view of a mammogram showing a high-density spiculated mass (red arrow) with heterogeneous linear clacifications in a ductal distribution (white arrows). These \"casting\" calcifications are characteristic of high-grade ductal carcinoma in situ [DCIS].) Pathology revealed infiltrating duct cell carcinoma with DCIS, comedo type.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa E Esserman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_40_36495=[""].join("\n");
var outline_f35_40_36495=null;
